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Abstract
The assessment and treatment of pain and burdensome symptoms is a complex entity 
in elderly nursing home patients with and without dementia. This thesis aims to 
investigate the efficacy of individual pain treatment on pain intensity in people with 
advanced dementia, and to explore the prescribing patterns of scheduled analgesic 
drugs in Norwegian nursing homes. Further, the thesis explores the change in pain 
and symptom intensity during pharmacological treatment in nursing home patients 
who are dying and investigates whether it is possible to estimate the day of imminent 
death in such patients.
Three different studies provide data for this thesis. In Paper 1 we use data from a 
multicentre cluster randomised controlled trial (cRCT): “The Impact of Pain on 
Behavioural Disturbances in Patients with Moderate and Severe Dementia” (Pain-
BPSD). Paper 2 is based on four data samples of scheduled analgesic drugs in 
Norwegian nursing homes between 2000 and 2011. For Paper 3, data are provided by 
a trajectory study entitled “Resource use and Disease Course in Dementia” (REDIC), 
that followed patients systematically from admission to a nursing home and over the 
course of three years or until death.
Aims
In Paper 1, we investigate the efficacy of a stepwise protocol of treating pain (SPTP) 
on pain intensity and Activities of Daily Living (ADL) in nursing home patients with 
moderate and severe dementia and behavioural disturbances. 
In Paper 2, we explore the prescribing patterns of scheduled analgesic drugs in 
Norwegian nursing home patients between 2000 and 2011, examining associations 
with age, gender, cognitive function, and type of nursing home unit.
In Paper 3, we study signs of imminent dying and change in pain and symptom 
intensity during pharmacological treatment in nursing home patients, from the day a 
patient was perceived as dying to the day of death.  
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Methods 
In Paper 1, we used secondary analyses from a 12-week cRCT including 352 patients 
with advanced dementia and behavioural disturbances from 18 nursing homes in 
Western Norway. The 60 clusters (single independent nursing home units) were 
randomised to intervention or control. Patients in the intervention group received 
individual treatment of pain with paracetamol (acetaminophen), morphine, 
buprenorphine transdermal system, and/or pregabalin. Participants who were
randomised to the control groups received care as usual. The primary outcome 
measure was pain intensity assessed with the Mobilisation-Observation-Behaviour-
Intensity-Dementia-2 (MOBID-2) Pain Scale. The secondary outcome measure was 
physical performance assessed by the Barthel ADL Index. Pain intensity scores were 
obtained from 327 patients (intervention n=164, control n=163) at four time points 
during the eight week intervention, with additional follow-up after a four-week wash-
out period. 
In Paper 2, we used secondary analyses of four nursing home samples (three 
observational studies and one cRCT) from 2000 (n=1926), 2004 (n=1163), 2009 
(n=850), and 2011 (n=1858), representing 14 Norwegian counties. Scheduled 
analgesic prescriptions were extracted from medication records, and the following 
groups were applied: peripheral analgesics (paracetamol and Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs)), weak opioids (codeine and tramadol), strong opioids 
(morphine, fentanyl, oxycodone, and buprenorphine), and adjuvant therapy 
(pregabalin, gabapentin, and amitriptyline). 
For Paper 3, we used data from a prospective, longitudinal trajectory trial including 
607 patients from 47 Norwegian nursing homes during the first year after admission. 
We assessed the time between admission and the day of death, pain and burdensome
symptoms, and pharmacological treatment during the last days and hours of life. Pain
and burdensome symptoms were investigated using the Edmonton Symptom 
Assessment System (ESAS) and MOBID-2 Pain Scale. The level of dementia was 
assessed with the Clinical Dementia Rating scale (CDR), physical performance with 
Karnofsky Performance Scale (KPS), and Physical Self-Maintenance Scale (PSMS). 
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Nutrition and bedsores were assessed with the Resident Assessment Instrument for 
Palliative Care (RAI-PC).
Results 
In Paper 1, we found that patients randomised to the intervention group conferred 
significant benefit from pain treatment on pain intensity compared with the control 
group at week 8 (P<0.001). After the four-week washout period between weeks 8 and 
12, the pain intensity increased significantly. The overall ADL function did not 
improve by pain treatment. However, participants who were treated with paracetamol 
improved their ADL function after eight weeks (P=0.022).
In Paper 2, we reported a 65% increase of the analgesic drug prescription in 
Norwegian nursing homes between 2000 and 2011. The prescription of paracetamol 
and opioids increased by 113% and 118%, respectively. Strong opioids (fentanyl, 
buprenorphine, morphine, and oxycodone) increased almost nine-fold from 1.9% in 
2000 to 17.9% in 2011 (P<0.001). Compared with individuals without dementia, 
people with dementia received fewer analgesics in 2000, 2004, and 2009, a difference 
we did not find in 2011.
In Paper 3, we showed that one in four patients died during the first year after nursing 
home admission. The identification of imminent dying was possible in 61% of the 
patients and was associated with increased fatigue and poor appetite. At the day of 
death, the administration of opioids, midazolam, and anticholinergic drugs increased 
significantly. The initiation of pharmacological treatment was associated with a 
reduction of pain intensity and symptoms such as anxiety. However, moderate and 
severe pain affected 60% of the patients on the day of imminent death, and was still 
high on the day of death (46%). Further, the prevalence of moderate and severe 
dyspnoea increased from 44% to 53% and death rattle from 8% to 19%, in the last 
days of life. Interestingly, respiratory symptoms such as dyspnoea and death rattle 
were not associated with the administration of opioids or anticholinergic drugs.
Conclusions
A stepwise protocol of treating pain (SPTP) improved the intensity of pain in people 
with dementia and those treated with paracetamol enhanced their ADL function. 
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Thus, it was substantial to find that the overall analgesic drug use increased from 
35% to 58% in nursing home patients between 2000 and 2011 and that prescribing 
patterns were equal in patients with and without dementia in the 2011 sample. We 
suggest further that the identification of imminent dying may be challenging in 
nursing home patients and people with dementia, leading to a high symptom burden 
on the day of death. Respiratory symptoms in particular tend to increase towards the 
time of death. Our findings emphasise the necessity for staff education together with 
non-pharmacological and pharmacological interventions to improve the situation of 
elderly individuals who are dying. 
This thesis mirrors the complexity of symptom assessment and treatment of pain and 
burdensome symptoms in our ageing population and highlights substantial needs for 
evidence-based implementation studies to investigate the efficacy of individual 
interventions in dying nursing home patients and people with dementia.  
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Sammendrag
Evaluering og behandling av smerte og belastende symptomer er utfordrende og 
komplekst hos eldre sykehjemspasienter og personer med demens. Denne
avhandlingen undersøker om individuell smertebehandling reduserer
smerteintensiteten hos personer med moderat til alvorlig grad av demens, samt
studerer utviklingen av foreskrevet smertemedisin (analgetika) over tid i norske 
sykehjem. Videre undersøker avhandlingen endring i smerte- og symptombelastning 
ved medikamentell behandling hos døende sykehjemspasienter, og om tidspunktet for 
nært forestående død er mulig å estimere.
Datagrunnlaget for avhandlingen er hentet fra tre ulike studier. I artikkel 1 brukes
data fra et multisenter klynge randomisert kontrollert studie (cRCT) “The Impact of 
Pain on Behavioural Disturbances in Patients with Moderate and Severe Dementia” 
(Pain-BPSD trial). Artikkel 2 anvender data fra fire utvalg av fast foreskrevet 
analgetika fra norske sykehjemspasienter fra 2000 til 2011. For artikkel 3 kommer 
data fra forløpsstudien “Resource Use and Disease Course in Dementia” (REDIC), 
som følger pasienter fra innleggelse i sykehjem og over tre år eller til personene dør.
Mål
I artikkel 1 undersøker vi om en stegvis protokoll for smertebehandling (SPTP) har
påvirker smerteintensitet og aktiviteter i dagliglivet (ADL) hos sykehjemspasienter 
med moderat til alvorlig grad av demens og agitasjon.
I artikkel 2 studerer vi utviklingen av fast foreskrevet analgetika i norske sykehjem
fra 2000 til 2011, og assosiasjoner til alder, kjønn, kognitiv funksjon og type 
sykehjemsavdeling (somatisk avdeling eller avdeling for personer med demens).
I artikkel 3 observerer vi mulige tegn på nært forestående død og endring i intensitet 
av smerte og andre belastende symptomer ved medikamentell behandling, blant annet 
bruk av analgetika, fra dagen en pasient ble vurdert som døende til dødsdagen.
Metode 
I artikkel 1 ble det utført sekundære analyser fra et 12-ukers klynge randomisert 
kontrollert studie (cRCT). I alt ble 352 sykehjemspasienter med moderat til alvorlig 
grad av demens og agitasjon inkludert fra 18 sykehjem på Vestlandet. Seksti 
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sykehjemsavdelinger (1 avdeling=1 klynge) ble randomisert til enten intervensjons-
eller kontrollgruppe. Pasienter i intervensjonsgruppen fikk individuell
smertebehandling med paracetamol, morfin, buprenorphin depotplaster og/eller 
pregabalin. Personer randomisert til kontrollgruppen mottok sin sedvanlige pleie og 
omsorg. Hovedutfallsmålet var forandring i smerteintensitet og ble evaluert med 
Mobilization-Observation-Behaviour-Intensity-Dementia-2 (MOBID-2) smerteskala.
Sekundært utfallsmål var fysisk funksjon målt med Barthel ADL Index. Data for 
smerteintensitet forelå for 327 personer (intervensjon n=164, kontroll n=163), og ble 
vurdert ved fire tidspunkt gjennom den 8 uker lange intervensjonen, i tillegg ble det 
utført en måling i uke 12 etter en periode på fire uker med utvask av medikamentet.
I artikkel 2 ble det brukt sekundære analyser av fire sykehjemsutvalg (tre 
observasjonsstudier, og en cRCT) fra år 2000 (n=1926), 2004 (n=1163), 2009 
(n=850) og 2011 (n=1858), i alt var 14 norske fylker representert.
Fast foreskrevet analgetika ble hentet fra medisinkort og gruppert slik; perifere 
analgetika (paracetamol og ikke-steroide antiinflammatoriske midler (NSAIDs)), 
svake opioider (codein og tramadol), sterke opioider (morfin, fentanyl, oxykodon og 
buprenorfin), og adjuvant terapi (pregabalin, gabapentin, og amitriptylin).
I artikkel 3 gjennomførte vi en prospektiv longitudinell forløpsstudie som fulgte 607 
pasienter fra 47 norske sykehjem gjennom deres første år etter innleggelse.  Vi kartla 
tiden fra dagen personen ble vurdert som døende og til dødsdagen, samt smerte og 
andre belastende symptomer, og medikamentell behandling som ble gitt i de siste 
timer og dager av livet. Symptomene ble evaluert med Edmonton Symptom 
Assessment System (ESAS) og MOBID-2 smerteskala. Grad av demens ble 
undersøkt med Klinisk Demens Vurdering (KDV), fysisk funksjon med Karnofsky 
Performance Scale (KPS) og Physical Self-Maintenance Scale (PSMS), ernæring og 
liggesår ble registrert ved hjelp av Resident Assessment Instrument for Palliative 
Care (RAI-PC).
Resultater
I artikkel 1 finner vi at en individuell og stegvis smertebehandling reduserer 
smerteintensiteten hos personer med demens. Etter en fire ukers utvask-periode fra 
uke 8 til uke 12 økte smerteintensiteten i intervensjonsgruppen signifikant. ADL 
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funksjonen viste ingen bedring eller forskjell mellom kontroll og 
intervensjonsgruppe, men personer som fikk paracetamol viste en økt ADL funksjon 
etter åtte uker (P=0.022).
I artikkel 2 viser vi at foreskriving av analgetika i norske sykehjem økte med 65 % fra
2000 til 2011. Foreskrivingen av paracetamol og opioider økte med henholdsvis 113
% og 118 %. Sterke opioider (fentanyl, buprenorphine, morfin og oxycodone) viste 
nesten en ni-dobling fra 1.9 % i 2000 til 17.9 % i 2011 (P<0.001). Sammenlignet med 
personer uten demens, hadde færre personer med demens foreskrevet analgetika i 
2000, 2004 og 2009, denne forskjellen fant vi ikke i 2011.
I artikkel 3 viste vi at 1 av 4 av pasienter døde i løpet av deres første år etter 
innleggelse i sykehjem. Nært forestående død var mulig å estimere hos 61 % and 
pasientene, og var assosiert med redusert allmenntilstand (fatigue) og redusert 
appetitt. På dødsdagen økte administrasjonen av opioider, midazolam og 
antikolinerge legemidler signifikant. En oppstart av medikamentell behandling var
assosiert med reduksjon av smerte og belastende symptomer som for eksempel angst. 
Likevel finner vi at moderat til alvorlig grad av smerte påvirket 60 % av personene da 
døden var nært forestående og var fremdeles høy på dødsdagen (46%). Videre fant vi 
at forekomsten av moderat til alvorlig grad av dyspné økte fra 44 % til 53 %, og
dødsralling fra 8 % til 19 % i de siste timer og dager av livet. Symptomer fra 
respirasjonssystemet var ikke assosiert med administrasjon av opioider eller 
antikolinerge medikamenter. 
Konklusjon
En stegvis protokoll for smertebehandling gir smertelindring for personer med 
demens og behandling med paracetamol øker ADL funksjonen. Det er således ett 
viktig funn at foreskriving av analgetika økte fra 35 % til 58 % bland
sykehjemspasienter fra 2000 til 2011, og særlig at foreskrivningen av analgetika for 
dem som har og dem som ikke har demens er lik i 2011. Resultater fra artikkel 3 kan 
tyde på at det er utfordrende å identifisere når døden er nært forestående, noe som kan 
føre til at pasienten kan oppleve en høy symptombyrde på dødsdagen. Særlig gjelder 
dette økning av symptomer fra respirasjonssystemet. Våre funn understreker behovet
for undervisning til personalet og implementering av medikamentell og ikke-
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medikamentell behandling for å bedre situasjonen for sykehjemspasienter og personer 
med demens. 
I tillegg til å gjenspeile kompleksiteten i evaluering og behandling av smerte og andre 
ubehagelige symptomer i vår aldrende befolkning, signaliserer denne avhandlingen 
behovet for kunnskapsbaserte implementeringsstudier som undersøker effekten av 
individuelle intervensjoner hos døende sykehjemspasienter og personer med demens.
1. Introduction
The global population is rapidly ageing, with substantial demographic changes the 
result of reduced birth numbers and mortality rates. An increased lifespan is expected 
globally because of better living conditions, fewer infections, and improved 
healthcare (WHO, 2012). The urbanisation of our societies makes the role of 
institutional care increasingly important for the aged, especially for elderly people 
living alone. One of the most important challenges is the care of people with chronic, 
age-related diseases, including those with cognitive impairment and dementia. In the 
last few decades, the number of people with dementia has increased to 35 million 
worldwide, and a doubling of this figure is expected during the next 30 years (Prince
et al., 2013).
About 78,000 people are currently living with dementia in Norway. The rate is 
particularly alarming amongst those living in nursing homes, as over 80% have 
dementia (Helvik et al., 2015). The majority of these individuals have moderate to 
severe stages of dementia, and most have high needs for treatment and care related to 
impaired physical and cognitive function, lack of memory and speech, 
neuropsychiatric symptoms, and complex co-morbidities (Selbaek et al., 2013).
Advanced age is also associated with increased prevalence of pain often triggered by 
the musculoskeletal system such as fractures and neuropathies (Husebo et al., 2008).
Recent documentation highlights that 40-60% of all nursing home patients are 
affected by daily pain (Achterberg et al., 2010, Husebo et al., 2011). People with 
moderate to severe dementia are no longer able to provide valid self-reports, and so 
best practice is for a caregiver (proxy-rater) with close knowledge of the person to 
evaluate the pain intensity by using a valid observational pain assessment instrument, 
before and after individual pain treatment has been initiated (Corbett et al., 2012).
The assessment and treatment of pain in people with advanced dementia is complex, 
and earlier reports documented substantial differences between analgesic drug 
prescriptions in elderly people with dementia compared with younger counterparts 
without cognitive impairment.  
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In Norway, 40,000 people die every year (SSB, 2016b), despite efforts and policies to 
enable more people to die in the security of their home, almost 50% die in a nursing 
home, 32% die in a hospital, and only 7-15% at home (SSB, 2016b).
To improve advanced care planning and end-of-life care in nursing home patients 
with and without dementia, mid- and short-term prognostication as well as pain and 
symptom management are key tasks. Conferring to the newest guidelines of The 
National Institute for Health and Care Excellence (NICE), entitled “Care of dying 
adults in the last days of life”, there is recognition of the fact identifying when 
someone is about to die is complex and so often goes unrecognised (NCCMH, 2015).
Proper and timely assessment and treatment of pain and burdensome symptoms in the 
last days and hours of life is challenged by methodological and ethical concerns. Only 
a few studies have undertaken the assessment and change in pain and symptom 
intensity alongside pharmacological treatment in a prospective design.
This thesis aims to explore the assessment and treatment of pain in people with 
dementia, the analgesic prescribing patterns over the last decade in Norway, and pain 
and symptom management at the end-of-life in Norwegian nursing home patients. As 
                                        Figure 1. Complexity of assessment and treatment in nursing home patients
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demonstrated in Figure 1, we included different research samples, methods, and time 
points to establish this.
This thesis is comprised of three papers, and the PhD candidate, Reidun K. Sandvik, 
collected data for Papers 1 and 3, and for the 2009 sample in Paper 2. The candidate 
contributed to the study design of Papers 2 and 3, and wrote the manuscripts for the 
three papers. Whilst Reinhard Seifert performed the statistical analysis for Paper 1, 




2.1 The ageing population
The development of the ageing population is caused by increasing life expectancy 
and the positive consequences of successes in the economy, welfare, and healthcare 
systems, both in the developed and in the developing world. Globally, the population 
is expected to have increased by 120% by 2050 from its figure in 1980. The 
proportion of persons 65 years and older will increase by 176%, from 6% in 1980 to 
16% by 2050 (UN, 2015). Importantly, the significant a decline in mortality rates and
rise in fertility rates hastens this process of demographic transition, particularly in 
Asia and Latin America (Prince et al., 2013). For the Western European countries, the 
development of the ageing population is also related to the post-World War II “baby 
boom” generation. 
Consequently, these demographic developments are putting a considerable strain on 
the healthcare services. Healthcare expenditures are challenging to estimate in 
advance, but politicians suggest financial tasks should increase, especially for the 
elderly generation. According to national figures, most citizens 67 years and older 
live in their own home without any daily support, with s only 6% in this age group 
living in an institution. The situation changes for the age groups 80- 90
years where 18% and 37% live in a nursing home, respectively. This is reflected in 
the demographic details of the nursing home population, which suggest that the 
service is primarily used for the old individuals, most of whom are women.
2.1.1 Nursing home care
Currently, about 41,000 nursing home beds are available in Norway. Upon 
admission, patients have a mean age of 85 years, with more detailed proportions for 
different age groups (80-89 years (43%); 90+ years (34%); 67-79 years (18%), and < 
66 years (5%)) (SSB, 2016b). The nursing home facility provides care for frail
patients, and the mean length of survival from admission to death is two years
(Vossius et al., 2015). The necessity for a place in a nursing home is often a 
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combination of moderate and severe care needs and mild to moderate dementia (SSB, 
2016a).
The ageing population is the largest and fastest growing group in the healthcare 
system. Thus, the likelihood for dementia has increased significantly in the nursing 
home setting and today about 84% of residents have dementia (Helvik et al., 2015).
Taking the demographic development into consideration, the required amount of
nursing home beds for people with dementia is expected to almost quadruple during 
the next 30 years (Vossius et al., 2015). Dementia related challenges such as 
neuropsychiatric symptoms, sleep disturbances, and pain are important triggers for 
nursing home admission. In addition to the mental decline, nursing home patients 
experience a huge burden by multiple diagnoses (multi-morbidity=two diagnoses and 
more) such as stroke, cancer, and cardiovascular, lung, and neurological diseases. On 
average, each patient will have four different diagnoses and about 70% have five 
diagnoses or more (Graverholt et al., 2011). The overall load of these problems, 
including cognitive decline has a devastating impact on the activities of daily living
(ADL) (Helvik et al., 2014).
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2.2 Dementia
Dementia is a chronic, usually progressive and incurable disease, with increased risk 
of neuropsychiatric symptoms and mortality (Selbaek et al., 2014). The term 
“dementia” comprises a range of different, burdensome symptoms affecting cognition 
and the ability to perform daily activities. 
A decline in cognitive functions such as memory, attention, problem solving, critical 
thinking, learning of new information, and orientation is most frequently described.
In the later stages of the disease, the person loses his or her speech ability, and 
challenges such as incontinence, muscle stiffness, and balance problems are common
(Edjolo et al., 2014). Most important for the person with dementia, their relatives, and 
also the nursing home staff are changes in the patient’s usual behaviour and the 
development of behavioural disturbances (BPSD) or neuropsychiatric symptoms 
(NPS) such as agitation and aggression, depression, anxiety, irritability, delusion, 
hallucination, and sleep and eating disturbances (Prince et al., 2013). Due to the 
overall progressive nature of dementia, life expectancy is significantly reduced in 
these people (Wolfson et al., 2001, Sachs et al., 2011, Brodaty et al., 2012).
2.2.1 Prevalence of dementia
The current prevalence of dementia in people 60 years and older is 4%, worldwide, 
with regional differences ranging from 2% in Africa to 6% in North America (Ferri et 
al., 2005), and 7% in Western European countries (Prince et al., 2013). The 
prevalence of dementia is age-related, which means that about 2% in the 60-64 age
group have dementia, a number that increases to 43% for those 90 years and older in 
Western European countries. During the next three decades, dementia prevalence will 
increase by 87% in Europe and 440% in Africa and Asia (Prince et al., 2013).
Despite this development, decreasing incidences of dementia have also been recently 
described in Western society (Jones and Greene, 2016). According to data from 
England collected between 1989 and 1994, the proportion of people with dementia 
was forecasted to be 8.3% in 2010. Repeated screening of the same area in 2008 
demonstrated, unexpectedly, a 1.8 % decrease in prevalence to 6.5% (Matthews, 
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2013). This declining incidence of dementia is supported by an American study that 
calculated the five-year prevalence of dementia from 1977 to 2008, and was able to 
report a decrease in dementia incidence from 3.6% to 2% (Satizabal et al., 2016).
Interestingly, Alzheimer’s disease (AD) and vascular dementia were found to be 
reduced by 30% and 50% in Northern America, respectively (Satizabal et al., 2016),
which the authors attribute to improved management of cardiovascular diseases and 
increased focus on lifestyle management, such as the reduction of stress and
unhealthy eating, and increased activities. Although the evidence shows a decline in 
the incidence of dementia, the prevalence of individuals with dementia will rise due 
to a large and fast growing ageing population.
2.2.2 Different types of dementia disease
Diagnosis of dementia, including stage and type of dementia, is usually based on the 
International Classification of Diseases, version 10 (ICD-10) (WHO, 2015) and 
Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5 coding 
update) (APA, 2013). According to the ICD-10, dementia is possible when a person 
over a period of at least six months shows memory decline (especially for new 
information) and other cognitive functions, such as thinking and problem solving.
This progressive syndrome causes decline in physical functioning and daily activities 
as well as social skills. Further, in persons with dementia, the awareness is preserved 
and the cognitive changes cannot be explained by depression or delirium. At least two 
of the following must be present: reduced ability to learn new skills, reduced ability 
in abstract thinking and reasoning, a decline in visuospatial function and language 
skills, and/or altered personality (Aarsland et al., 2011).
The physician Dr. Alois Alzheimer, was one of the first scientists who described AD
with declined cognitive function and neuropsychiatric symptoms, and linked this to 
pathological findings in his famous patient, Auguste Deter (Alzheimer, 1907, 
Stelzmann et al., 1995). The detection of AD in 1906 was later confirmed by others 
and covers the largest group of neuro-degenerative brain diseases (Yen et al., 1987, 
Dickson et al., 1988). There is increasing evidence that AD is caused by plaques 
consisting of beta amyloid and neurofibrillary tangles. AD is a progressive disorder 
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with a preclinical stage, in addition to a mild, moderate, and severe stages. Together 
with Lewy bodies, Parkinson dementia, frontotemporal dementia, and Chorea 
Huntington, AD accounts for about 70 % of all dementia cases (Ott et al., 1995). The 
second largest group are people with vascular dementia (20%), caused by damage to 
blood vessels in the brain, which reduces the supply of nutrition and oxygen. Stroke 
caused by blood clotting or haemorrhage, or chronically damaged vessels after high 
blood pressure, diabetes or lupus are the main underlying diseases causing vascular 
dementia (Roman et al., 1993).
Less than 10% of dementia cases involve the disease as a secondary cause of another
disease, such as brain trauma, cerebral cancer, vitamin insufficiency or infections.
In nursing home patients, comorbid AD and vascular dementia (mixed dementia) 
(Scherder et al., 2003b, Husebo et al., 2008, Perl, 2010) are most frequently observed. 
Mixed dementia is very common, and comprise about 50% of all cases (Jellinger and 
Attems, 2010).
2.2.3 Assessing stages of dementia
The first stage of dementia is mild, which involve increased memory loss, 
concentration problems, and reduced performance in instrumental ADL like social 
interactions and work performance. This evolves into moderate dementia, which 
constitutes a more severe impairment in memory, speech, and lower performance in 
instrumental ADL functions, and personal ADL like toileting and dressing might be 
affected. The final stage is severe dementia, in which extensive assistance in required 
for all ADL functions. At this stage, the person will have problems with speech, 
memory loss, and other cognitive functions. 
In all stages neuropsychiatric symptoms such as delusions, hallucinations, and 
agitation can be seen (Bergh et al., 2011).
Over the last decades, a range of cognitive tests has been developed to screen for 
dementia or to evaluate cognition. The numerous amounts of instruments evaluate
global cognitive function, or various specific cognitive aspects like attention, praxis 
or orientation, or the levels of dementia (Reisberg et al., 1997). Screening tools for 
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dementia, such as the Mini Mental State Examination (MMSE), must be able to 
discriminate between people with normal cognitive function and those with mild 
cognitive impairment or mild dementia (Folstein et al., 1975). Instruments to evaluate 
the severity of dementia used proxy rated information in addition to in depth 
knowledge of the person, both to screen for dementia and determine the stage of 
dementia. Commonly used such tools are the Clinical Dementia Rating Scale (CDR) 






According to the International Association for the Study of Pain (IASP), pain is 
defined as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (IASP, 2012). Pain is 
complex, and a multidimensional experience for the person who is living with the 
pain (Tracey and Dickenson, 2012). The reduction of verbal communication abilities 
does not ameliorate the experience of pain intensity, as stated clearly by the 
following: “The inability to communicate verbally does not negate the possibility that 
an individual is experiencing pain and is in need of appropriate pain-relieving 
treatment” (IASP, 2012).
Melzack and Casey (1968) suggest that the neurological pain pathways of pain 
perception are comprised by different pain systems: the sensory-discriminative 
(intensity, location, and quality of pain), the motivational-affective (emotional 
experience of pain, motivation, and pain affect), and the cognitive-evaluative 
(attention, anticipation, and memory) pain system (Melzack and Casey, 1968). These 
functions are related to the medial and lateral cerebral structures. In addition, an 
autonomic-endocrine system with the responsibility for stress reactions (Tsigos and 
Chrousos, 2002) and a central area for behavioural pain processes have  been 
suggested (Monroe et al., 2012).
2.3.2 Pain types
Important for the clinician, there are two main types of pain: nociceptive and
neuropathic pain. Nociceptive pain covers pain from the musculoskeletal system 
(somatic pain) and pain related to internal organs (visceral pain), whereas neuropathic 




Somatic pain is caused by the nociceptive activation of the skin, muscles, and 
skeleton by diseases such as arthritis, fractures, skin conditions, or bursitis. Free 
well-localised sensation to the spine via the dorsal root ganglion (Pasero and 
McCaffery, 1999). Elderly nursing home patients and people with dementia are 
especially affected by these conditions (Husebo et al., 2008), with 36% of home 
dwelling elderly people experiencing moderate to severe painful episodes (Cayea et 
al., 2006). The aging process dries the lumbar discs, causes arthritis, and 
osteoporosis, and leads to increases in tumours in the spine and muscle tissue (Jones 
et al., 2014). Studies from our group found that pain-related diagnoses of 
osteoporosis, fractures, and arthritis are most prevalent, affecting about 30% of the 
patients living in a nursing home (Husebo et al., 2008). The most frequent pain 
locations are related to the musculoskeletal system and especially hips, shoulders, and 
back (Husebo et al., 2010).
Visceral pain may originate from internal areas in the chest, abdomen, kidney or 
urinary bladder. Signals are transmitted via small diameter unmyelinated C-fibres 
transmitting dull, acing, and poorly localised signals (Pasero and McCaffery, 1999).
Examples of painful conditions originating from the viscera are urine tract infections, 
ulcers, liver conditions, and irritable bowel syndrome (Moloney et al., 2015). In 
nursing home patients, nephrolithiasis, duodenal ulceration, or prostatitis may cause 
chronic or acute pain (Gloth, 2001). Investigations by our group demonstrate that 7% 
of nursing home patients have pain related to a skin/wound diagnosis, but twice as 
many have pain located in the skin (14%) (Husebo et al., 2008, Husebo et al., 2010).
Although musculoskeletal pain is most frequently described, pain related to the 
urogenital organs (21%), abdomen (17%), and head/mouth/neck (16%) affects a 
substantial proportion of these individuals (Husebo et al., 2010). Notably, the 
prevalent numbers regarding orofacial pain are inconsistent, depending on age, 
aetiology, and setting investigated (Lipton et al., 1993, Riley and Gilbert, 2001). It is 
suggested that 40% of all older adults have pain in the oral cavity due to problems 
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such as infections or dry mouth caused by anticholinergic medication use (Jones et 
al., 2000, Toxopeus et al., 2014).
Neuropathic pain 
The IASP states that neuropathic pain is caused by lesions or diseases of the 
somatosensory nervous system (Treede et al., 2008), which can be located in different 
origins and then referred to peripheral or central neuropathic pain. Peripheral 
neuropathic pain is defined as “pain caused by a lesion or disease of the 
somatosensory nervous system” (Dworkin, 2012). Relevant diagnoses causing this 
type of pain are trauma to the first neuron, injury caused by damage to small vessels, 
and damage caused by chemotherapy or infection (Gilron et al., 2015). Diabetes 
related polyneuropathy or neuropathic pain in connection with the amputation of an 
extremity, are further causes of chronic pain. Central neuropathic pain is defined as 
“pain caused by a lesion or disease of the central somatosensory nervous system.” A
diagnosis of stroke, demyelination in connection with multiple scleroses, or Vitamin 
B12 myelopathy may cause central pain, especially in elderly people (Treede et al., 
2008). The degeneration of spinal discs with related nerve compression or a cerebral 
tumour may also cause this type of pain.
2.3.3 Transmitters
A neurotransmitter is a chemical substance released by neurons as an impulse of 
information from one neuron to another or addressed to a muscle cell, organs, or 
other tissue. Typical pain transmitters are glutamate, substance P, calcitonin gene-
related peptide, serotonin, and bradykinin (Latremoliere and Woolf, 2009).
2.3.4 Pain characteristics
The prerequisite for competent treatment of pain is proper assessment of the most 
typical pain characteristics: duration, location, quality, and intensity of pain. 
Pain duration less than three months is defined as acute pain which serves to protect 
the body by the noxious stimuli of an injury, trauma, disease or surgery (Pasero and 
McCaffery, 1999). Chronic or persisting pain continues over time and may last many 
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years (Ready and Edwards, 1992). In chronic pain, the lack of meaningful function 
converts this state into an illness (Woolf et al., 2004).
Pain location identifies the source of pain and gives important information about the 
cause of the symptom or disease. This feature is mediated by the somatosensory 
cortex and a part of the lateral pain system. However, identification of pain location 
may be hampered by sensory inputs from different origins to the same nerve plexus,
for example from the stomach to the heart region or the projection of pain (e.g.,
cholecystitis to the right shoulder) (Tucker et al., 2014).
Pain quality describes the patient’s sensation of pain with words such as burning, 
itching, sickening, acing, throbbing, sharp, or others. This specification of quality 
alongside the location, history, and duration of pain are important elements that 
enable the initiation of appropriate treatment (Victor et al., 2008). Even with the same 
intensity and location of pain, the quality can differ and help distinguish between 
aetiologies. 
Pain intensity is the most often assessed factor to describe the patient’s pain 
experience, to initiate pain treatment, or to evaluate the efficacy of pain management. 
Pain perception in general is a complex interaction of different brain regions, already 
processed in early stages of the cerebral perception process (Iannetti et al., 2005). To 
measure the intensity of pain in cognitively intact people, self-rating instruments such 
the McGill Pain Scale (Melzack, 1975), Face Pain Scale (Hicks et al., 2001), Visual 
Analog Scale (VAS), or the Numeric Rating Scale (NRS) (Hawker et al., 2011) are 
usually used. The VAS is a line with two ends corresponding to no pain and severe 
pain. The NRS is an equivalent to the VAS with as an 11-point Likert scale ranging 
from 0 (no pain) to 10 (most severe pain). 
2.3.5 Pain in nursing home patients and people with dementia 
Reports of pain prevalence in nursing home settings have increased over the years,
and show a considerable variation in their estimates of pain occurrence in this setting. 
For instance, Takai et al. (2010) performed a review and found that pain affects between 
3.7%  83% of patients (Takai et al., 2010). The vast variation might be associated to and
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differences in period of assessment, pain intensity assessed, procedures to collect the 
data institutional settings, stages of cognitive impairment, or simple staff competence 
(Zwakhalen et al., 2009, Takai et al., 2010, McAuliffe et al., 2012). To exemplify 
this, an investigation of excruciating pain found a prevalence of 3.7%, whereas a 
dichotomous investigation of pain /no pain found that 73% of the nursing home 
patients were in pain (Teno et al., 2004, Asghari et al., 2006). According to 
investigations using the Minimum Data Set (MDS) in European and North American 
nursing homes, pain presence varies from 32% in Italy to 65% in the United States 
(Achterberg et al., 2010, Shen et al., 2015).
Self-report of pain with validated pain assessment instruments are the “Gold 
standard” in pain assessment (Hawker et al. 2011). In people with mild dementia or 
mild cognitive impairment, self-report will also be the first choice (Hadjistavropoulos 
et al., 2014). In general, a valid self-report is more difficult to attain in people with 
moderate and severe dementia (MMSE total score <18) (Scherder et al., 2001, Lukas 
et al., 2013). However, other studies found that people with advanced dementia were 
able to judge their pain state (Closs et al., 2004, Zwakhalen et al., 2009).
Epidemiological studies report higher, lower, and the same prevalence of pain in 
people with and without dementia (Leong and Nuo, 2007, Shega et al., 2010, 
Docking et al., 2015, van Kooten et al., 2016). An important requirement in people 
with dementia is evaluation of their cognitive impairment using a tool like the 
MMSE, and to choose a validated pain assessment instrument accordingly. In 2008, 
the assessment of pain prevalence using such a validated observational pain 
behaviour instrument reported that about 60% of nursing home patients with
dementia have mild to severe pain (Husebo et al., 2008).
2.3.6 Pain indicators in people with advanced dementia 
Impaired language and abstract thinking puts older people with dementia at risk for 
under-treatment of their pain because of impaired self-report capacity 
(Hadjistavropoulos et al., 2014). Observation of the person’s usual behaviour is key 
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when differentiating between behaviour that might be related to dementia and 
behaviour related to pain. 
About 35 different observational pain behaviour instruments have been developed, 
validated, and reviewed in the literature during the last three decades (Corbett et al., 
2012, Flo et al., 2014, Lichtner et al., 2014). Observation based pain instruments are 
used by a proxy-rater, usually the primary caregiver. These tools are mainly based on 
the observation of the patients’ typical behaviour, which possibly is changed as a 
reaction when experiencing pain. The American Geriatric Society Panel (AGS-Panel)
described typical pain behaviours expressed by people with dementia (Table 1)
(AGS-Panel, 2002, Hadjistavropoulos et al., 2014).
Table 1. Behaviours related to pain in persons with dementia as described by the AGS Panel.
Pain behaviour Example of behaviour
Facial expression Grimacing, brow lowering, mouth opening, closing eyes 
Verbalization, vocalization Moaning, groaning, crying, complaining 
Body movements Pulling away, rubbing, freezing, limping, clenched fists 
Change in interpersonal interactions Aggressive, affect, combative, resisting care, difficult to 
console
Changes in activity patterns/routines Wandering, appetite change, sleep disturbances 
Mental status changes Crying, confusion 
Despite this essential progress, there are still considerable challenges to assess pain in 
people with dementia because proxy-rating and judgment by others has to replace 
self-report procedures of pain intensity, pain affect, pain quality, pain location, 
patient history (duration of pain), and physiological changes. In people with advanced 
dementia, the assessment of observed pain behaviour can simply be a suggestion as it 
cannot guarantee the actual pain state, and can never be as valid as a self-report.
In addition, most older adults (>90%) experience chronic pain that they have adapted 
to, and will therefore avoid painful movements (pain avoidance effect) (Vlaeyen and 
Linton, 2012). Pain related to the musculoskeletal system appears through 
standardised guided movements, whereas pain related to the internal organs, head, 
and skin is more hidden and difficult to quantify (Husebo et al., 2007).
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2.3.7 Observational pain behaviour instruments
To our knowledge, the first tool developed and tested to assess pain behaviour in 
people with dementia was the Facial Action Coding System (FACS) (Ekman and 
Friesen, 1978). The instrument evaluates anatomical features of the patient’s face 
during induced pain stimulus and categorises reactions in different units of the face. 
By means of the FACS, it has been shown that people with dementia have even more 
facial reactions compared with those without cognitive impairment (Kunz et al., 
2009). Since the development of the FACS in 1978, scientists and clinicians have 
worked constantly at the development of new approaches, resulting in a number of 
different types of pain tools currently being available. In Table 2 below we list the 12 
most promising pain instruments according to a recent review (Husebo et al., 2012).
However, it is noteworthy that not all these instruments are tested in relation to all
aspects of validity and reliability, and only few fulfil the newest recommendations by 
the consensus-based standards for the selection of health measurement instruments
(COSMIN) group, including psychometric properties of responsiveness (Mokkink et 
al., 2006, Angst, 2011). Although the scales are widely used, basic elements like 
instructions for staff education and how to interpret the results are not always 
established, affecting the feasibility of the scales. 
Responsiveness of observational pain behaviour instruments
According to the COSMIN protocol, responsiveness is defined as the “ability of an 
instrument to detect change over time in the construct to be measured” (Mokkink et 
al., 2010). Until now, seven of the 35 observational pain assessment instruments for 
people with dementia have been tested for responsiveness in four studies (Husebo et 
al., 2016). Morello et al. (2007) explored the psychometric properties of the Elderly 
Pain Caring Assessment 2 (EPCA-2), which rates the pain intensity in non-
communicating elderly people by eight behavioural items with two dimensions: the 
signs outside and during caregiving (Morello et al., 2007). Cohen-Mansfield (2008) 
conducted an open pain treatment trial and highlighted the PAINE and PADE pain 
tools to be most responsive to assess the change in pain intensity scores (Cohen-
Mansfield and Lipson, 2008). In the third study by Rat et al., they conducted an open 
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pain treatment trial to investigate the responsiveness of the acute pain instrument, 
Algoplus® (Rat et al., 2011). These studies are important contributions to evaluate 
the efficacy of pain treatment and change in pain intensity after pain treatment has 
been initiated. However, methodological issues flaw them, some studies are 
underpowered or lack a power calculation, thy have a high drop-out rate, or no 
control group to compare changes over time with the intervention groups (Husebo et 
al., 2014b). Our own group investigated the responsiveness of the MOBID-2 Pain 
Scale, using data from a cluster randomized clinical trial that included 352 
Norwegian nursing home patients with moderate and severe dementia and agitation 
(Husebo et al., 2011). In this study, we followed the latest COSMIN 
recommendations and found the MOBID-2 Pain Scale to be responsive to change
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medical drugs are classified by the Anatomical Therapeutic Chemical Classification 
System (ATC) (WHO, 2011). Analgesic drugs are covered by the ATC-system N02 
for analgesics and M01 for NSAIDs. Adjuvant therapies with for instance N03A 
antiepileptics (gabapentin and pregabalin) or N06AA for tricyclic antidepressants 
(TCA) cover drugs that have primary indications other than pain relief but may also 
be affective in case of neuropathic pain.
The primary classes of analgesics are divided into peripheral and central acting drugs
also demonstrated by the Pain Treatment Ladder developed by the World Health 
Organisation’s (WHO, 2016a) (Figure 2):     
Figure 2. Pain Treatment Ladder according to the WHO
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2.4.2 Pain treatment recommendations
Currently, several practice recommendations for the treatment of pain in elderly 
people are available. A non-systematic literature search revealed eight guidelines and 
position statements on pharmacological pain management for older adults and long-
term care patients (Table 3). Pain treatment guidelines for people with dementia are
not yet available, although a recent systematic review exists on the efficacy of 
analgesic drugs on pain intensity in persons with dementia (Husebo et al., 2016). The 
authors conclude that there is weak evidence on analgesic drugs used in persons with 
dementia due to small and underpowered studies with no randomisation a and lack of 
adequate pain assessment tools (Husebo et al., 2016). We have provided a range of 
recommendations based on the guidelines that can be found in Appendix 1, Table 4.
Table 3. Clinical guidelines for pharmacological treatment in older adults
Guideline Author
Long term care
Pain in residential aged care facilities. Management strategies APS (2005)
Pain management in the long-term care setting AMDA (2012)
Older adults
The management of persistent pain in older persons AGS-Panel (2002)
Pharmacological management of persistent pain in older 
persons
AGS-Panel (2009)
Multidisciplinary guideline 'Recognition and treatment of 
chronic pain in vulnerable elderly people
Achterberg et al. (2012)
Guidance on the management of pain in older people Abdulla et al. (2013)
Position statements
Transforming long-term care pain management in North 
America: the policy-clinical interface
Hadjistavropoulos et al. 
(2009)
Position statement 21: Pain in older people ANZSGM (2012)
Identifying and Managing Pain in People with Alzheimer´s 
Disease and Other Types of Dementia: A Systematic Review
Husebo et al. (2016)
2.4.3 Analgesic drug prescription in Norway
Analgesic drug use in the general population
During the last decade, the overall consumption of analgesic medication did not 
change in Norway. We analysed numbers from the Norwegian Prescription Database 
(NorPD) and found the proportion of analgesic drug (ATC N02+M01) users to be 
30% in 2004 and 32% in 2014 (NorPD, 2016). However, the proportion of daily-
dispensed doses increased by 23% between 2004 and 2014. Although the overall 
proportion of persons prescribed analgesics may be unchanged in recent years, the 
proportion of dispensed paracetamol increased from 3% to 8%, whereas NSAID 
prescribed declined from 18% to 16% in this period.  The proportion of persons using 
opioids (ATC N02A) increased slightly from 9% to 10.5%, and whilst the 
prescription of morphine and fentanyl remained stable from 2004 to 2014, the 
prescription of oxycodone and buprenorphine increased fivefold from 0.1 to 0.6%, 
and 0.05 to 0.3%, respectively.
The increased consumption of opioids in the general population of Norway is 
consistent with findings from a population-based study of opioid prescription rates in 
people with cancer and non-cancer pain, using data from the NorPD (Fredheim et al., 
2010). Non-cancer pain is increasingly managed by tramadol, buprenorphine, and 
oxycodone. The use of morphine and fentanyl remains stable but the use of codeine 
has slightly decreased for non-cancer pain (Fredheim et al., 2013).
Figure 3 demonstrates the analgesic drug prescription for elderly people 75 years and 
older, based on the NorPD data in 2014. We find that the proportion of individuals 
using paracetamol and buprenorphine increases with age, whereas NSAIDs are less
frequently prescribed as age increases (NorPD, 2016).
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Figure 3. Proportion of prescribed analgesics drugs in Norway (2014) displayed by age categories
according to data from the Norwegian Prescription Database (NorPD)
2.4.4 Analgesic drug prescription in nursing home patients and 
people with dementia
Over 20 years ago, Ferrell et al. demonstrated the vast pain intensity experienced by 
nursing home patients and the under-prescription of analgesic agents in people with 
dementia (Ferrell et al., 1990, Ferrell, 1995). Since then, under-treatment of pain has
been documented in different countries and settings (Scherder and Bouma, 1997, 
Allen et al., 2003, Nygaard et al., 2003, Closs et al., 2004, Nygaard and Jarland, 
2005, Achterberg et al., 2007, Reynolds et al., 2008, De Souto Barreto et al., 2013).
Analgesic drugs are more extensively prescribed to nursing home patients compared
with age matched home-dwelling people, particularly paracetamol and opioids 
(Haasum et al., 2011, Johnell and Fastbom, 2012, Jensen-Dahm et al., 2014).
However, NSAIDs are more usual in home-dwelling older adults possibly because
they are available over the counter (Haasum et al., 2011, Johnell and Fastbom, 2012).
Most analgesic prescription studies in nursing home patients do not report the 
patients’ pain intensity scores or the potential pain relieving effect alongside the 
prescription numbers. A Dutch study including 350 nursing home patients
investigated residents at baseline and after six months in regards to pain intensity and 
analgesic consumption. The pain intensity was recorded on an ordinal scale as no, 






























opioids, and others. Although individuals with severe pain received more opioids and 
more combination therapy, this study found that severe pain after six months was 
associated with baseline pain (OR 18.55, 95% CI 5.19–66.31). This result may 
indicate that pain treatment was not adapted fully to the individuals’ pain intensity,
especially since fewer than 45% of the residents received any analgesics despite 
having pain (Smalbrugge et al., 2007).
Analgesic prescribing patterns seems to be influenced by level of dementia. Despite 
the same painful diagnoses, more persons without and with mild dementia were 
administered analgesics compared with those suffering from moderate and severe 
dementia (Closs et al., 2004). Reynolds et al. (2008) also included persons without 
dementia and those with mild, moderate, and severe dementia, finding that 
individuals with no or mild dementia were prescribed an analgesic drug more often 
than people with moderate and severe dementia. Interestingly, analgesic drugs given 
as needed and nonpharmacological interventions seem to be stable across groups 
(Reynolds et al., 2008).
Morrison et al. (2000) demonstrated that people with dementia after hip fracture 
surgery did not receive the same amount of analgesic drug prescription compared 
with patients without dementia (Morrison and Siu, 2000). New evidence suggests that
an equal proportion of persons with and without dementia receive paracetamol and 
opioids after hip surgery, although people with dementia receive lower doses of 
opioids at day one and two after surgery compared with older adults without 
dementia (Jensen-Dahm et al., 2016).
In general, we find that Nordic studies report an increase of analgesic drug
prescriptions in the elderly and people with dementia. In Finland, for instance, the 
prescription of paracetamol increased from 34% to 47%, opioids from 12% to 23%, 
and adjuvant therapy from 1% to 5%, between 2003 and 2011. Especially, the use of 
strong opioids increased from 2% to 14% in this period (Pitkala et al., 2015).
A Swedish study of home-dwelling and nursing home patients aged 85 years and 
older, demonstrated that those with dementia were treated more frequently with 
paracetamol compared with people without dementia, whereas the amount of opioids 
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was similar in both groups (Lovheim et al., 2008). Another study from Sweden, the
National Study of Aging and Care – Kungsholmen (SNAC-K), found that people 
with dementia were more often treated with both paracetamol and opioids. Even after 
adjusting for painrelated diagnoses, dementia, age, sex, and setting, the likelihood for 
analgesic drug use was significantly increased in those with dementia compared to 
others (Haasum et al., 2011).
Comparable trends are observed in a Danish study that explores the opioid drug 
prescriptions (Jensen-Dahm et al., 2014) of elderly people living at home or in a
nursing home. Home-dwelling people with dementia were found to receive more 
analgesics compared with persons without dementia. In nursing homes, it was 
discovered that opioids are slightly less often prescribed in people with dementia
compared with people with no dementia (35% vs 43%). Strong opioids were found to
be equally prescribed between the groups: buprenorphine was more often used in 
people with dementia (12.3%) compared with persons without dementia (9.5%) 
(Jensen-Dahm et al., 2014).
2.4.5 Efficacy of treating pain on pain intensity in people with 
dementia
Despite the increasing analgesic drug use in nursing home patients and people with 
dementia, there remains a considerable dearth of studies that evaluate the effects of 
analgesic drugs on pain intensity in these people (Flo et al., 2014). Until now, only 
few studies investigate the efficacy of treating pain on neuropsychiatric behaviour or
pain intensity (Pieper et al., 2013, Husebo et al., 2016). Currently, only two
prospective studies with more than 10 participants are available using a validated pain 
assessment instrument to assess the efficacy of analgesic drugs on pain intensity
(Buffum et al., 2004, Husebo et al., 2011). So far, the evidence finds that paracetamol 
(acetaminophen) can be recommended for the treatment of pain in people with 
dementia in doses as high as 3g/day (Buffum et al., 2004, Chibnall et al., 2005), and 
that morphine is effective for people with dementia when the doses are individualised 
(Manfredi et al., 2003).
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2.5 End-of-life care in the nursing home
In Norway, about 19,000 people or 48% of the dying population pass away in a 
nursing home (SSB, 2016b). This implies that most of the patients admitted to a 
nursing home will also die in this setting. In the last days and hours of their lives, 
nursing home patients may experience pain and burdensome symptoms that require
proper end-of-life care and treatment. Most of these people will have dementia with a
mean length of survival between five and nine years (range 1 to 16 years) (Davies et 
al., 2004). Our own REDIC report demonstrates a mean survival rate of eight years
(Vossius et al., 2015).
Dementia is a progressive and life limiting disease that requires proper treatment and 
care with high focus on quality of life (QoL) (van der Steen et al., 2014). The WHO
defines end-of-life care (palliative care) as the “approach to improve the QoL of
patients and their families facing the problems associated with life-threatening illness, 
through the prevention and relief of suffering by means of early identification and 
impeccable assessment the treatment of pain and burdensome symptoms” (WHO, 
2016b).
Whereas the principles of palliative care are well established in dying cancer patients 
(Black et al., 2011), such care remains under-studied and not yet available for dying 
nursing home patients and people with dementia. One important prerequisite for 
dignified dying is the staff’s ability to identify the end-of-life and the day of 
imminent dying (Mitchell et al., 2009). Recognising dying is vital in order to provide 
individual treatment, communication, and ethical decision making (NCCMH, 2015).
In people with dementia, one of the main challenges may be the lack of active 
feedback regarding effects and side effects of the treatment. Additionally, reduced 
consciousness and delirium may impair the self-report capacity. A relevant answer 
may be the identification of typical symptoms that characterise a three- to six-month 
mortality risk or symptoms unique to imminent death. Pneumonia (41%), repeated 
episodes of fever (53%), and eating problems (86%) have been related to an increased 
six-month mortality risk in people with dementia (Mitchell et al., 2009), and other 
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symptoms such as breathlessness and dyspnoea (46C), pain (39%), and pressure 
ulcers (39%) are characteristic of the last three months of life (Mitchell et al., 2009).
Preparing communication and Advance Care Planning
Advance Care Planning (ACP) involves health care plans by preparing 
communication and necessary decisions for future treatment and care. Unfortunately, 
nursing home patients and people with dementia are often poorly informed and less 
included in ACP (Forbes et al., 2000). When important decisions need to be taken, 
the central person will no longer be able to participate in important ethical decisions,
and thus cannot be asked about their preferences, values, and choices. This can lead 
to unfortunate and random decisions. As such, the inclusion of the patient, relatives, 
and health care workers (including the responsible physician) should be initiated 
before the patient is unable to communicate their own preferences (Flo et al., 2016).  
2.5.1 Cancer care versus dementia care in the dying 
ACP, ethical decision making, and the proper assessment and treatment of pain and 
burdensome symptoms are the hallmarks of dignified end-of-life care in dying people
(Flo et al., 2016, van der Steen et al., 2014). These approaches are widely developed, 
tested and described in the literature in people with cancer (Theis et al., 2007). The 
newest NICE guidelines review the emerging literature and provide evidence-based
recommendations to ameliorate the suffering in the dying adult (NCCMH, 2015). The
document also underlines the importance of identifying imminent death as a 
prerequisite to initiating changes in treatment regimes, communication, and up-start 
with pain and symptom management. The evaluation of these actions, especially the 
efficacy of the medication on pain and burdensome symptoms, are highlighted by the 
NICE guideline.
Although these procedures are implemented and routinely used on palliative care 
wards and in hospices and hospital units, end-of-life care for dying elderly people and 
those with dementia are less developed, implemented, and tested. Indeed, the NICE 
guidelines did not find one single randomised control trial or prospective study of a 
high quality that included nursing home patients or people with dementia (NCCMH, 
2015).
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Our current knowledge, developed by research and clinical experiences related to 
palliative care for cancer patients cannot easily be transferred to nursing home 
patients and people with dementia (van der Steen et al., 2014), because whilst they 
may die in the same setting, people with dementia die differently than patients with 
cancer. Data derived from the MDS comparing 1609 dying people with dementia and 
883 patients dying from cancer in nursing homes reported significantly more 
burdensome interventions used in the former patient group, including feeding tubes, 
blood tests, and restraints used during the 120 days before death (Mitchell et al., 
2004). Another smaller comparison between patients on a palliative care ward in a 
nursing home and usual nursing home patients with multi-morbid nursing home 
patients who suffer from cardiovascular diseases, degenerative skeletal illnesses, and 
neurological complaints, including dementia, demonstrates relevant differences. 
Cancer patients are often younger, cognitively intact, and prepared for death as a 
result of participation in communication and ethical decisions over a longer time 
period (Husebø et al., 2004). They also received pain and symptom management, 
which is vital in this critical period of life. 
2.5.2 Assessment and treatment of pain and burdensome 
symptoms in the nursing home
In general, the main burdensome symptoms in dying patients are pain, dyspnoea,
anxiety, delirium, and death rattle (Chang et al., 2000). It has been suggested that the 
occurrence of these symptoms is common among the vast majority of all dying
patients (Husebø et al., 2004). In the palliative care setting these challenges can be 
sufficiently relieved by subcutaneous application of morphine, scopolamine/robinul, 
haloperidol, and midazolam (Sutton et al., 2003). It has been suggested that acute 
heart failure enhances sensations of dyspnoea, death rattle, and suffocation, thus 
increasing the need for morphine as the only effective treatment in the final hours of 
life (Twycross, 1997). Importantly, these observations are less investigated 
prospectively in the elderly. To our knowledge, only a few studies explore palliative 
care in nursing home patients and people with dementia (Brandt et al., 2005a, Brandt 
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et al., 2005b, Brandt et al., 2006a, Brandt et al., 2006b, Mitchell et al., 2009, 
Hendriks et al., 2014, Klapwijk et al., 2014, Hendriks et al., 2015).
Four reports have been provided by the same underlying study, investigating different 
aspects in end-of-life care for dying nursing home patients (Brandt et al., 2005a,
Brandt et al., 2005b, Brandt et al., 2006a, Brandt et al., 2006b). In all, 516 Dutch 
nursing home patients were included by a nursing home physician when life 
expectancy was suggested to be less than six weeks. Main symptoms providing this 
prognosis were little or no fluid intake (43%), fatigue (32%), and little or no appetite 
(25%) (Brandt et al., 2005a).
The prediction of survival in nursing home patients is challenging and depends on
close knowledge of the person (Brandt et al., 2006b). In this sample, 91% died within 
the estimated six weeks, with median survival of three days. An accurate prediction 
of survival was possible when death occurred within seven days and estimated to 
93%, thereafter the accuracy dropped to 16% (Brandt et al., 2006b). A smaller 
selection of 463 patients of the same sample was investigated for burdensome 
symptoms in their last 48 hours, and showed a reduction in pain and burdensome
symptoms towards death. Within two weeks after the patient died, the nursing home 
physician assessed the patient’s symptom burden for two time periods; 48-24 hours 
before death, and 24-0 hours before death using the ESAS tool and the Resident
Assessment Instrument for Palliative Care (RAI-PC). Although they found an 
amelioration of symptoms, the burden is still high during the last 24 hours of life as 
shortness of breath (23%), pain (22%), anxiety (21%), and nausea (17%) affect the 
person to a substantial degree on the day they die (Brandt et al., 2006a).
Another Dutch observational study included 36 patients expected to die within the 
next seven days (Klapwijk et al., 2014). Twelve died before any assessments were 
made, which left 24 patients. Two nursing home physicians performed all the
assessments no longer than two weeks after the patients died using the Mini Suffering 
State Examination (MSSE), the PAINAD, the DS-DAT, and the End of Life in 
Dementia scales-Comfort Assessment in Dying (EOLD-CAD). The different tools 
found different severities of symptom burdens, with the MSSE evaluating patients 11 
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times in seven days and reported 35.5% to be in pain, whereas the EOLD-CAD 
investigated pain six times, and found pain present in 15% of the assessments. 
Further, they found that all patients received morphine in their last week of life
(Klapwijk et al., 2014).
Another Dutch study was performed and reported in two different papers (Hendriks et 
al., 2014), both of which focused on the prevalence of pain, dyspnoea, and agitation, 
along with the treatment provided to the symptoms investigated. The study followed 
372 patients with dementia from admission to a nursing home, 218 of whom died 
during follow-up; the nursing home physician was able to complete a retrospective 
assessment of 213 of these individuals. In addition, 119 retrospective assessments 
from eligible patients were added, with 330 patients in total. The first paper reports 
on symptom severity and treatment provided in the last week of life in dying nursing 
home patients with dementia (Hendriks et al., 2014). This study found higher 
intensity scores compared with previous studies, with pain affecting 52% of 
individuals in the last week of life, and dyspnoea and agitation affected 35% of the 
patients. The symptom severity did not differ with dementia severity in this study. 
Pain was most frequently addressed using opioids (67%), paracetamol (60%), and 
NSAIDs (17%). 
The second paper reports on the longitudinal follow-up with assessments every six 
months over 3.5 years (Hendriks et al., 2015), and found that in the last week of life, 
78% patients suffered pain, 52% had dyspnoea, and 35% were agitated. Further, this 
study found that parenteral opioid drug use was increasingly provided for pain (61%), 
whereas morphine (69%) and oxygen (40%) were increasingly used to treat 
dyspnoea, and nonpharmacological interventions (50%), anxiolytics (62%), and 
antipsychotics (44%) were increasingly used to treat agitation in dying patients with 
dementia in their last week of life. The assessment of the three symptoms was 
dichotomised, which might be the reason for the higher symptom prevalence found in 
this study. 
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2.5.3 End-of-life care assessment instruments
Several instruments are available to explore different aspects of end-of-life care in the 
nursing home and relatives’ and caregivers’ satisfaction with the care, quality of 
death and dying, and the prediction of death (van Soest-Poortvliet et al., 2012). We 
only discuss assessment tools related to symptom management, and a brief 
description of relevant tools is presented in Table 5, Appendix 2.
The Edmonton Symptom Assessment System (ESAS) includes nine different items
for pain and symptoms (pain, fatigue, nausea, appetite, depression, anxiety, dyspnoea,
drowsiness, and well-being), validated by severity scores on an 11-point Likert scale 
(0 = not present, 10 = as bad as possible) (Bruera et al., 1991). The ESAS instrument 
has been validated for validity and reliability in a range of settings, such as palliative 
care units, hospitals, and nursing homes (Nekolaichuk et al., 2008). It has also been
validated for proxy-rating (Pautex et al., 2003, Nekolaichuk et al., 1999a, 
Nekolaichuk et al., 1999b), in people with dementia (Yang et al., 2016), and in dying 
nursing home patients (Brandt et al., 2006a). However, ESAS is not validated in 
dying nursing home patients with dementia.
The most complete and frequently used assessment instrument is the RAI-PC with 15 
domains of symptoms, physical and mental status, communication, and 
administrative items (Steel et al., 2003). The RAI-PC has a dichotomous scoring 
system for absence and presence of each symptom, which, however, may reduce the
feasibility to assess treatment efficacy. The tool is validated in several languages and 
it is available in Norwegian (Steindal et al., 2014).
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3. Aims of the thesis
3.1.1 General aims
This thesis investigates the efficacy of individual pain treatment on pain intensity in
people with advanced dementia, and explores the prescribing patterns of scheduled 
analgesic drugs in Norwegian nursing homes. Also, the thesis explores the change in 




To investigate the efficacy of a stepwise protocol for treating pain on pain intensity 
and ADL in nursing home patients with moderate and severe dementia and agitation.
Paper 2
To explore the prescribing patterns of scheduled analgesic drug use in Norwegian 
nursing home patients from 2000 to 2011, with the association with age, gender, 
cognitive function, and type of nursing home unit.
Paper 3
To examine whether it is possible to determine signs of imminent dying and to
investigate the change in pain and symptom intensity during pharmacological 
treatment in nursing home patients, from the day a patient was perceived as dying to 





We conducted secondary analysis from data derived from the Pain-BPSD Study 
entitled “Efficacy of treating pain to reduce behavioural disturbances in residents of 
nursing homes with dementia: Cluster randomised clinical trial” (Husebo et al., 
2011). This was a cRCT investigating the effects of a stepwise protocol for treating 
pain (SPTP) over eight weeks, with an additional four-week wash out period. All 
patients were followed regularly with defined primary and secondary outcome 
measures at baseline and weeks 2, 4, 8, and 12. 
Setting and participants
In all, 352 nursing home patients with advanced dementia and agitation representing 
60 clusters or units from 18 nursing homes located in five municipalities in Western 
Norway were included. One nursing home unit was defined as one cluster to prevent
crossover contamination from the intervention to the control group. Nursing home 
units were allocated randomly by a statistician to either their usual care (N=177) or to
the SPTP (N=175). For this secondary analysis, we included patients with a pain 
intensity score assessed by MOBID-2 Pain Scale at baseline (N=327), allocated to the 
control (N=163) or intervention (N=164) group.
Eligibility criteria
Patients could be included if they were 65 years or older, showing severe agitation 
(Cohen-Mansfield Agitation Inventor 39), and had moderate or severe 
stages of dementia according to the Diagnostic and Statistical Manual of Mental 
Patients were excluded if they had a severe mental health disorder, had been resident 
in the nursing home
known allergy to the study medication. 
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Primary and secondary outcome measures 
All assessment scales can be found in Table 6, Appendix 3. The primary outcome 
measure was the MOBID-2 Pain Scale, an observational pain assessment tool 
administered by nursing staff. Pain is assessed in two parts containing a total of 10 
items related to the musculoskeletal system and internal organs, head and skin. The
assessment of pain intensity is based on observed pain behaviour related to 
vocalisation, facial expression, and defensive body positions. Musculoskeletal pain is 
assessed during five standardised guided movements (part 1 of the MOBID-2) 
performed during morning care. As an example, this comprises the movement of the 
hands, shoulders, back, legs, and torso. In addition, five items of visceral pain are 
recorded by staff observation over time (part 2 of the MOBID-2). Further, a body 
drawing for pain location is available. Each item is evaluated on a 10-point Likert 
scale for pain intensity (range 0-10). Based on all information, an independent overall 
10-point numeric rating scale is completed. The MOBID-2 Pain Scale is tested 
regarding validity, reliability, and responsiveness (Husebo et al., 2007, Husebo et al., 
2009, Husebo et al., 2010) and indicates no or mild pain (range 0-2), moderate pain 
(range 3-6), and severe pain (range 7-10).
A secondary outcome measure was personal ADL (P-ADL) assessed with the Barthel 
ADL Index. This tool ranges from 0-20, with lower scores indicating higher 
dependence in ADL functions on ten items (eating, bathing, grooming, dressing, 
bowel function, continence, toileting, transfer from bed to chair, mobility and stair 
use) (Mahoney and Barthel, 1965).
The screening tool used to assess cognitive function was the Mini-Mental State
Examination (MMSE), a 30-point interview administered by the research nurse or 
staff in which a higher score means better cognitive function. Cognitive skills 
covered by the instrument include orientation, recall, calculation, memory (short and 
long term), language, executive function, and visuospatial function. After initial 
development and testing, the tool has proven to be sensitive, valid, and reliable, 
including in later validations (Folstein et al., 1975, Pangman et al., 2000), and has 
been tested for nursing home patients in Norwegian (Engedal et al., 1988).  In 
addition, we assessed the level of dementia using the Functional Assessment Staging 
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(FAST) ranges from no dementia to severe dementia (1/2=no dementia; 3= mild; 4/5 
= moderate; 6/7 = severe) (Reisberg, 1988).
Intervention
Patients assigned to step 1 were treated with oral paracetamol 3 g/day (Table 7). If 
this was already provided at baseline, patients were allocated to step 2 (oral 
morphine, maximum 20 mg/day). If swallowing problems were present, patients were 
allocated to step 3, which was buprenorphine transdermal patc
Persons with neuropathic pain started on step 4 (oral pregabalin, maximum 300 
mg/day) (Table 7). In general, the treatment was individual and based on the 
individual’s ongoing pain management at baseline; if needed, different analgesics
could be combined.
Table 7. Stepwise protocol for the treatment of pain





1 No analgesics, or low dose 
of paracetamol
Paracetamol 3g/d 112 (68)
2 Full dose of paracetamol, 
or low dose of morphine 
Morphine  5mg x 2/d-10 mg x 2/d 3 (2)
3 Low dose of 





4 Neuropathic pain Pregabalin 25mg x 1/d-300mg/d 12 (7)
Statistics
We calculated the mean, standard deviation, and range for participant demographics. 
The differences between groups were tested with two-sample independent t-tests for 
normally distributed continuous variables. Categorical variables showing normal 
distribution were analysed by proportion of sample size and the chi-square test. Non-
normally distributed categorical variables were analysed using the Mann–Whitney U 
test.
Further, we investigated the mean and standard error of the MOBID-2 Pain Scale and 
Barthel ADL Index scores over time between groups with linear random intercept 
quantile mixed effects models, using the nursing home as nestling level. 
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The statistical significances of the p-values were considered as follows: highly 
significant (P<0.001), significant (P<0.005), and moderately significant (P<0.05). 
The statistical analyses were conducted with IBM SPSS Statistics for Windows 
version 21.0 (IBM Corp, Armonk, NY), R version 3.0.0 (The R Foundation for 
Statistical Computing, Vienna, Austria), and package nlme-3.1-109.
Ethics
Verbal and written informed consent was obtained directly in conversations with 
cognitively intact nursing home patients. If a patient was not able to consent on his or 
her own behalf, verbal and written informed consent was obtained in direct 
conversation with the patient (if possible) and his or her next of kin or legal guardian.
The study was registered by ClinicalTrials.gov number NCT01021696 and the 
Norwegian Medicines Agency (EudraCT nr: 2008-007490-20). It was further 
approved by the Regional Committee for Medical Ethics, Western Norway (REK-
Vest 248.08) in accordance with the local law.
4.1.2 Paper 2
Design
Trend analysis of analgesic drug prescriptions in four study samples.
Setting and participants
In Paper 2 we extracted information from medication records of scheduled 
medication from four different studies sampled in 2000, 2004, 2009, and 2011. 
The first sample from 2000 investigated the association between the use of 
constraints and patient and nursing home unit characteristics (Kirkevold et al., 2004).
In all, this study included 1926 patients representing 222 nursing home units from 54 
municipalities in Norway. The patients included were sampled from regular somatic 
wards (160 wards, 1362 patients) and special care units (91 wards, 564 patients) to 
ensure those with dementia were included. Between March and November 2000, 12 
specially-trained research nurses asked the patients’ primary caregivers about the 
suffering the patients experienced during their last seven days of life.
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Data from the second sample were collected in 2004 and derived from a study 
exploring the prevalence of NPS in people with various stages of dementia, and the 
association between NPS and psychotropic drug use (Selbaek et al., 2007). The data 
included 1163 patients from 26 small, medium, and large nursing homes, representing 
18 municipalities and four counties. Structured interviews with the patients’ primary 
caregivers were conducted by 16 registered nurses who had completed a two-day 
training course on dementia and neuropsychiatric symptom assessment.
The 2009 sample was the screening data for the Pain-BPSD study containing 850 
patients from 18 nursing homes in Western Norway. This study is further presented in 
Paper 1. 
The fourth sample (2011) is a follow-up of the study performed in 2004. In 2011, 25 
of the 26 nursing homes were investigated repeatedly, and 41 new nursing homes 
were added. In all, 1858 patients were examined, including the 99 patients who were 
investigated in both the 2004 and 2011 samples. 
Outcome variables
We collected the demographic variables age and gender, and also obtained the type of 
ward, level of dementia (using the Clinical Dementia Rating (CDR) or FAST), and 
the patients’ diagnoses. The CDR assesses level of dementia on six domains 
(memory, orientation, reasoning, social activities, instrumental, and personal 
activities), each assessed from 0-3, with a total sum of boxes ranging from 0-18. The
total score of the CDR is calculated based on an algorithm giving precedence to 
memory. This total score ranges from no dementia to severe dementia (0=no
dementia; 0.5=very mild; 1=mild; 2=moderate; 3=severe). The CDR shows valid 
psychometric properties and is widely used in the nursing home setting (Hughes et 
al., 1982, Selbaek et al., 2008). Furthermore, it is also available in Norwegian. The 
FAST situates the level of dementia on a seven-point scale from no dementia (1) to 
severe dementia (7). The FAST also show good psychometric validation and is 
widely used in Norwegian.  In our study, dementia w
FAST>3 (Reisberg, 2006).
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We coded the medication according to the ATC system and divided analgesics into 
meaningful groups: peripheral analgesics (paracetamol and NSAIDs), weak opioids 
(codeine and tramadol), strong opioids (morphine, fentanyl, buprenorphine, and 
oxycodone), and adjuvant therapy (pregabalin, gabapentin, and amitriptyline). The 
ATC codes used were as follows: any analgesic (N02), paracetamol (N02BE01), 
NSAIDs (M01A-H), codeine (N02AA59), tramadol (N02AX02), morphine 
(N02AA01), fentanyl (N02AB03), buprenorphine (N02AE01), oxycodone 
(N02AA05), pregabalin (N03AX16), gabapentin (N03AX12), and amitriptyline 
(N06AA09).
Statistics
We calculated the mean, standard deviation, and range for participant demographics. 
The differences between groups were tested with two-sample independent t-tests for 
normally distributed continuous variables. Categorical variables showing normal 
distribution were analysed by proportion of sample size and the chi-square test. We 
used mixed-model multivariate regression with the nursing home as the nesting level 
to investigate prescribing patterns. We also used logistic regression to understand the 
impact of sample year on the analgesic prescription.
Statistical significance of the p-values were considered as follows: highly significant 
(P<0.001), significant (P<0.005), and moderately significant P<0.05). 
The statistical analyses were conducted with IBM SPSS Statistics for Windows 
version 21.0 (IBM Corp, Armonk, NY) and STATA/IC 13.1
Ethics
In 2000, 2004, and 2011 patients and their next of kin were informed about the study 
design and their possibility to withdraw from inclusion and at any stage of the study.
In accordance with local law, ethical approval was granted by the Regional 
Committee for Medical Ethics, South and East Norway (REK-South/East) for 2004 
(61-04001) and 2011 (2010/1894). The 2009 sample was registered at 
ClinicalTrials.gov (NCT01021696), and approved by the Norwegian Medicines
Agency (EudraCT nr: 2008-007490-20) and the REK-Vest South and East Norway 
(REK-South/East) for 2004 (61-04001) and 2011 (2010/1894). The 2009 sample was 
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registered at ClinicalTrials.gov (NCT01021696), and approved by the Norwegian 
Medicines Agency (EudraCT nr: 2008-007490-20) and the REK-Vest (248.08).
4.1.3 Paper 3
Design
We use data from the Resource Use and Disease Course in Dementia Trial (REDIC).
This is an ongoing trajectory study (2012-2017) including four cohorts: 1. Home-
who receive domiciliary care (N=1000); 2. 
Healthy older adults living at home ; 3. Nursing home 
,
and 4. P
Baseline assessment was performed within four weeks after admission to a nursing 
home. At day of imminent death and day of death, the patient’s primary caregiver 
called the responsible research nurse at the day when the patients were suggested to 
be imminent dying and at the day of death. The assessment was carried out as an 
interview based on the last 24 hours. We included the medication administered in the 
last 24 hours as regular prescriptions and medication administered “as needed”.
Setting and participants
This paper uses data from the nursing home cohort where patients were followed 
from admission (baseline) and with assessments every 6 months for 3 years or until 
death. In all, 47 nursing homes were included from Hedmark (7 nursing homes, 43 
nursing home units), Oppland (22 nursing homes, 88 nursing home units), Nord-
Trøndelag (13 nursing homes, 26 nursing home units) and Bergen (5 nursing homes, 
25 nursing home units). 
Eligibility criteria 
Patients were eligible for inclusion if newly admitted to a nursing home and 65 years 
or older, or young and with a diagnosis of dementia. We excluded persons with a life
expectancy less than 6 weeks.
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Outcome variables
The pharmacological treatment was grouped as follows: opioids (weak and strong), 
anticholinergic drugs (morphine-scopolamine, scopoderm, glycopyrronium bromide), 
antiemetic drugs (metoclopramide, odansetron and haloperidol), anxiolytic/sedatives 
(benzodiazepines and derivates). The ATC codes used were opioids (N02A), 
anticholinergic drugs (A03AB/A04AD/N02AG01), antiemetic drugs 
(A04AA/N05AD01) and anxiolytic/sedatives (N05BA/N05CD08).
Assessment scales
To assess the patients` ADL function, we included the PSMS scale which comprises
of six domains such as toileting, eating, dressing, grooming, transfer, and bathing. 
The PSMS scale ranges from 6-30, increasing score means increasing dependence in 
daily functioning (Lawton and Brody, 1969). Physical function was also assessed 
using the KPS, which is a staging of function from normal (100) to dead (0) in 11 
steps (Vincent, 1984) (Crooks et al., 1991).
Burdensome symptoms at the end-of-life were assessed using the Edmonton 
Symptom Assessment System including nine symptoms. At end-of-life six relevant 
items for the end-of-life not included in the ESAS was extracted from the Resident 
Assessment Instrument- Palliative Care (RAI-PC) (sleep quality, vomiting, delirium, 
agitation, death rattle, and constipation).
Statistical analyses
We calculated the mean, standard deviation and range for participant demographics. 
The differences between groups were tested with two-sample independent t-tests for 
normally distributed continuous variables. Categorical variables showing normal 
distribution were analysed by proportion of sample size and the chi-square test. Non-
normally distributed categorical variables were analysed using the Mann–Whitney U
test.
Further, we examined the differences between groups and over time with regression 
models for repeated measurements with random intercept effects, linear mixed model 
for continuous and multilevel logistic regression for dichotomous outcome variables.
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Statistical significance of the p-values were considered as follows; highly significant 
(P<0.001), significant (P<0.005), and moderately significant (P<0.05).
Statistical analyses were conducted with IBM SPSS Statistics for Windows version 
21.0 (IBM Corp, Armonk, NY) and STATA/IC14.
Ethical aspects
Verbal and written informed consent was obtained directly in conversations with 
cognitively intact nursing home patients. If a patient was not able to consent on his or 
her own behalf, verbal and written informed consent was obtained in direct 
conversation with the patient (if possible) and from his or her next of kin or legal 
guardian.
The REDIC study is registered at ClinicalTrials.gov, number NCT01920100 and 




Sandvik, R., Selbaek, G., Seifert, R., Aarsland, D., Ballard, C, Corbett, C., 
Husebo, BS. Impact of a stepwise protocol for treating pain on pain intensity in 
nursing home patients with dementia: A cluster randomized trial.  Eur J Pain
2014:18;1490-500.
At baseline, >70% of the participants had at least one pain related diagnosis. 
Assessed using the MOBID-2 Pain Scale, 80% (n=282) had a total pain intensity 
score of >
Patients suspected of suffering from neuropathic pain had higher pain intensity 
scores (MOBID-2 Pain Scale mean 6.1, P=0.001) compared with patients with 
musculoskeletal pain (MOBID-2 Pain Scale mean 3.65) at baseline. 
Individual treatment of pain following a SPTP led to significant improvements to 
the pain intensity compared with the control group, after two weeks (average 
treatment effect (ATE) -0.703, SE 0.24, P=0.004). The effect continued to week 8, 
comprising a 45% changeover time and between groups (ATE=-1.393, SE 0.3, 
P<0.001).
The use of paracetamol ameliorated the pain intensity at week 2 (ATE=-0.67, 
P=0.010), week 4 (ATE=-0.92, P<0.001), and week 8 (ATE=-1.30, P<0.001). 
Treatment with buprenorphine transdermal system and extended release morphine 
reduced the pain intensity scores in week 8 (ATE=-1.14, P=0.008). 
Pregabalin had a conferred effect, showing a total pain intensity reduction of 64% 
from week 0 to week 8 (ATE=-3.53, P<0.001). 
Compared with the control, the ADL function did improve in the intervention 
group (week 8, P=0.443). However, patients receiving paracetamol demonstrated 
improved ADL function from baseline to week 8, compared with the control 
group (ATE=+1.00, P=0.022). 
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Paper 2
Sandvik, R., Selbaek, G., Kirkevold, O., Aarsland, D., Husebo, BS.Analgesic 
prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend 
analyses of four data samples. Age Ageing 2016:45;54-60.
Between 2000 and 2011, the analgesic drug prescriptions increased from 35% to 
58% in Norwegian nursing homes.
Paracetamol was most commonly prescribed and increased from 23% to 48%, 
followed by opioids (11% to 24%) and adjuvant therapy (1% to 4%). 
The use of strong opioids (morphine, buprenorphine, oxycodone, and fentanyl) 
increased almost nine-fold from 2% to 18%.
The prescription of NSAIDs decreased from 7% in 2000 to 3% in 2011 (P<0.001).
Women received more analgesics than men in all age groups: <80 (P<0.001), 81–
90 (P=0.001), and 91+ (P<0.001). 
Prescription of analgesic drugs increased with age.
The proportion of patients prescribed concomitant analgesics increased from 3% 
to 5% for paracetamol and weak opioids, respectively, between 2000 and 2011 
(P<0.001).
The prescription of any analgesic drug was significantly related to the absence of 
dementia in the 2000 (P=0.028), 2004 (P=0.027), and 2009 samples (P=0.011), 
but this was not found in 2011 (P=0.737).
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Paper 3
Sandvik, R., Selbaek, G., Bergh, S., Aarsland, D., Husebo, BS. Signs of imminent 
dying and change in symptom intensity during pharmacological treatment in 
nursing home patients. A prospective trajectory study. J Am Med Dir Assoc
2016: 10.1016/j.jamda.2016.05.006.
One in four newly admitted nursing home patients died during the first year.
Patients who died during the first year had more severe dementia (P=0.006), high 
dependency (P<0.001), pain in the mouth (P=0.003), nutritional substitutes 
(P=0.006), bedsores (P=0.008), and more severe symptoms of dyspnoea 
(P<0.001), drowsiness (P=0.001), fatigue (P=0.001), less well-being (P=0.025),
and reduced appetite (P=0.003) compared with those who survived the first year 
after admission.
Staff members were able to identify the day of imminent dying in 61% of the 
patients by signs of increased fatigue (OR 1.8, 95% CI 1.16; 2.85, P=0.009) and 
poor appetite (OR 1.2, 95% CI 1.06; 1.41, P=0.005). 
From the day of imminent dying to the day of death, the administration of weak 
opioids (3.7% vs. 37.3%, P<0.001), anticholinergic agents (6.2% vs. 18.6%, 
P<0.001), midazolam (8.6% vs. 17.2%, P<0.001), and strong opioids (48.1% vs. 
65.7%, P<0.001) increased significantly. 
Between the day of imminent dying and the day of death, the prevalence of 
several symptoms decreased, such as pain (60% vs. 46%, P<0.001), low sleep 
quality (50% vs. 38.2, P<0.001), anxiety (44% vs. 31%, P<0.001), depression 
(33% vs. 15%, P<0.001), nausea (24% vs. 12%, P<0.001), constipation (24% vs. 
8%, P<0.001), and delirium (16% vs. 3.1%, P<0.001).  
Despite declining symptom severity, patients still experienced pain (46%), sleep 
problems (40%), and anxiety (31%) on the day of death. 
Respiratory symptoms such as dyspnoea (44% vs.53%, P=0.040) and death rattle 
(8 vs. 19%, P<0.001) increased significantly during the last days of life.
Initiation of opioids was associated with the reduction of pain (P=0.041) but it 
was not related to dyspnoea.
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6. Discussion
We live in a very particular death-denying society.  We isolate both the dying and the 
old, and it serves a purpose.  They are reminders of our own mortality.  We should 
not institutionalize people.  We can give families more help with home care and 
visiting nurses, giving the families and the patients the spiritual, emotional, and
financial help in order to facilitate the final care at home.
                                                                                       Elisabeth Kübler-Ross, 1969
6.1 General considerations
This thesis aims to investigate the prevalence of analgesic drug prescription over 
time, and the efficacy of treating pain and burdensome symptoms in Norwegian 
nursing home patients. People with and without dementia were included and a broad
approach of outcome measures was used. The comprehensive tasks made different 
statistical analyses necessary. My work demonstrates a complexity faced by 
municipal healthcare professionals every day. The following discussion aims to 
enhance the quality of the work through a more critical appraisal, and to influence the 
clinical practice positively and to provide some implications for future research. 
Interestingly, our publications received high acknowledgement by editorials (Breivik, 
2014, Achterberg, 2016), engaged colleagues, and the media, which demonstrates 
that the field of elderly care and symptom management in nursing homes is of high 
relevance for researchers, clinicians, and society.
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6.2 Methods
6.2.1 Paper 1: A Cluster Randomized Controlled Trial (cRCT)
To investigate the efficacy of a pain management intervention, we chose to use cRCT 
as this has been described as a Gold Standard for this type of research (Stolberg et al., 
2004). The statistical structures of cRCTs were introduced in healthcare research 
groups for the first time by Cornfield (1978), who also demonstrates that the 
procedure is less efficient compared with randomisation of single individuals to the 
control and intervention group (Cornfield, 1978). The reduced efficacy is caused by 
the fact that patients, responders, or proxy-raters are related to one cluster, group, or 
unit and thus might answer more similarly than individuals who give individual 
responses (Donner and Klar, 2004). In our study, precautions were taken to blind 
research assistants and caregivers to group allocation. However, despite these efforts 
cRCTs will always be difficult to blind completely because of the requirements in a 
nursing home setting and the risk of contamination (Husebo et al., 2011). To meet 
this disadvantage of reduced efficacy, the number of participants has to be increased 
and the intra cluster correlation coefficient is an important element in the statistical 
analyses. To meet these challenges, we adopted the sample size number as described 
in an earlier publication (Husebo et al., 2011).
A further criticism of cRCTs in general is that they are often produced under 
controlled conditions with a selected group of people, and thus exclude older adults 
and people with dementia (Rothwell, 2005). Multi-morbidity and polypharmacy are 
well-known reasons for exclusion and lead to the underrepresentation of this group of 
patients in relation to the assessment and management of pain. However, untreated 
pain is an important challenge in dementia and is known to trigger neuropsychiatric 
symptoms such as agitation, depression, and sleep disturbances (Ahn and Horgas, 
2013). This recent article is the first study to explore specifically the effect of pain 
management on the intensity of pain in nursing home patients with advanced 
dementia. Our study is produced under comparable conditions to the participants’ 
daily lives as it is performed in the nursing home setting. These circumstances were 
also highlighted by Breivik (2014), who emphasised in his editorial that this 
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publication changed the current evidence from lowest (authors’ opinions) to highest 
(cRCT) level (Breivik, 2014).
The internal validity of a study reflects the causal relationship between the variables
studied. Hence, strong internal validity is the absence of systematic or random 
error/bias. A systematic error can be a recall bias, selection bias, allocation bias, 
background variables/confounders, misclassification/-stratification, and performance 
or detection error and error due to dropouts. The results might happen by chance, due 
to a random error, or in the form of a causal relationship (Akobeng, 2008).
In Paper 1, the internal validity is suggested to be strong especially regarding the 
random errors. Baseline data are equally distributed among the two groups and 
reduce the likelihood for allocation bias. The large number of patients with pain 
intensity scores at baseline included (n=327) is sufficient to detect change with 
significant levels of P<0.001 and thereby rule out type 1 errors (reject true 
hypothesis), and large enough to rule out type 2 errors (fail to reject false hypothesis) 
as the power was calculated and the needed number was exceeded. We suggested a 
Hawthorne effect, also referred to as a motivation bias, which might relate to staff 
learning or anticipation of effect. This effect did not last over time and the 
intervention group conferred benefits from the intervention at all time points 
compared with the control group. Our robust randomisation, large number of patients 
and clusters, and statistical testing using nursing home and cluster as nestling levels 
in multilevel mixed models, should be sufficient contextual factors to avoid
systematic bias. The trial was not blinded with a placebo but both the individual and 
the caregiver rating were blinded to avoid performance bias. The results were not 
affected by a systematic difference due to drop-out rates as they were equally 
distributed between the control and intervention groups during the eight weeks of 
intervention.
Since we used secondary analyses of a cRCT that investigated the efficacy of treating 
pain on agitation, the prevalence of pain was not one of the inclusion criteria. Future 
studies should include patients with dementia and clinical relevant pain at baseline. In 
Figure 4, we show a mixed effect multi-level modelling that includes 203 patients 
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intensity 
scores between the control (mean 5.3 SE 0.2, n=99) and intervention (mean 5.4 SE 
0.2, n=104) group, at baseline (P=0.642). Excluding persons without pain, the 
baseline pain intensities were higher compared with the original findings. The 
intervention group showed a significant change from baseline, but only slightly larger 
compared with the original findings in Paper 1 (ATE -1-74, SE 0.30, P<0.001). The 
change was in large parts due to the change in the control group. 
Figure 4: Pain intensity scores assessed by MOBID-2 Pain Scale in the control and intervention 
groups during eight weeks of treatment and a four-week wash-out period. Only people with baseline 
scores 3 were included.
6.2.2 Paper 2: An Epidemiological Study
We performed an observational trend study including four study samples to 
investigate analgesic drug prescriptions in Norwegian nursing homes, from 2000 to 
2011. The analgesic drug prescriptions trend towards an increase, as from 2000 to 
2011 we found a 65% increased prescription. Another important finding was that the 
analgesic drug prescription was related to having dementia until 2009, but in 2011 we 
found an equal prescription and no relation to dementia in 2011. Age and gender 
affected individually the prescribing patterns: women and the oldest old received 
most analgesics. This suggests that age and gender must be adjusted for in future 
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studies estimating probabilities in analgesic prescription and also as confounding 
factors. 
Our study is limited by the fact that with the exception of the 99 patients examined in 
both 2004 and 2011, none of the included 5,798 patients were evaluated more than 
once. This means that we are not able to report trend analyses within the single 
cohorts but can only demonstrate the trend of analgesic use over one decade, in 
general. In addition, we did not register the doses, duration, and use of ‘as needed’ 
medication. Another weakness is the lack of valid pain intensity scores assessed by a 
validated pain tool, before and after pain treatment was started. Thus, we are not able 
to answer the question of whether the treatment was administrated effectively and the 
right patient received the right medication and at the right time. In the nursing home 
setting, inappropriate prescribing patterns and medication errors have been prevalent
(Haasum et al., 2012).
The four study samples we have contain medication records from studies that were 
already collected. This means that each study was already performed and varied in
criteria for eligibility, education of assessors, and the study aim. This might have 
introduced bias to the study selection because there were different nursing homes that 
were selected for different reasons for the different study samples. We could have 
investigated the same patients over time prospectively, but in addition to being a 
costly method it does not answer how analgesic drug use has developed until now. 
We could have included only the sample of 2004 and 2011 since they used the same 
nursing homes with the same criteria for inclusion/exclusion and the same research 
question and variables. However, by including the 2000 sample we were able to 
answer how the prescription of analgesic drugs changed over a whole decade.
Regional variations in analgesic prescription may have influenced our results. 
However, as we use methods comparable with those adopted in other studies, and 
also find a comparable result, we suggest that the impact of local variations on the 
analgesic prescription is low (Pitkala et al., 2015).
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All epidemiological studies introduce the question of covariates and variable 
selection. The selection of what variables to include is important either to rule them 
out as confounding factors, or background factors (Fletcher et al., 2012).
We used the nursing home as nestling level, suggesting a control for preferences by 
the prescribing doctors and educational packages of pain treatment provided. We also 
adjusted all analyses for listed variables, such as age, gender, and type of nursing 
home unit. There still might be confounding variables that we were not able to 
collect, especially clinical variables of pain intensity, delirium, and side effects of 
analgesic drug use. Further, the introduction of guidelines or educational packages 
may be relevant variables affecting the analgesic prescribing pattern in Norwegian 
nursing homes. 
6.2.3 Paper 3: A Prospective Trajectory Study
A prospective trajectory design following a cohort with individual assessments from 
admission to a nursing home and for three years or until death is robust enough to 
rule out recall and selection bias. Patients living in a nursing home for many years are 
potentially a different population compared with the newly admitted people included 
in our study. All participants met the same inclusion and exclusion criteria and were 
assessed by the same variables and tests. Compared with Paper 2, these data are not 
constrained by existing data sets. 
There are some limitations to the rigour of the prospective design, as well. Data are 
produced under the conditions of staff learning and motivation, and thereby symptom 
reporting can be influenced by learning and result in over reporting of clinical 
symptoms such as pain and anxiety. More importantly, it is not clear how the 
prospective follow-up of patients and caregivers acts as an intervention. Staff might 
score a symptom and thereby give a medication, or justify medication provided due to 
the symptoms scored. 
We imposed a cut-off of one year on time from admission to death. The advantage of 
a one-year cut-off is to identify clinical symptoms related to a trajectory into the last 
days and hours of life. This might introduce a misclassification bias for some subjects 
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dying shortly after where the cut-off is placed and will be so wherever this cut-off is 
placed. We suggest that one year is valid because only two patients died the first 
month after admission, and we are now able to distinguish clearly between groups.
Medication data administered on the day of imminent dying and the day of death 
were collected prospectively and directly by telephone interview between the 
responsible nurse and the research assistant. Whilst this was a time-consuming 
procedure, we still suggest that it is the most effective and correct registration of 
ongoing treatment, which also included the “as needed” medication. 
Previous longitudinal studies have used fixed assessments over a time period in
nursing home patients with dementia (Mitchell et al., 2009), retrospective 
assessments of the last year with last assessment three months before death 
(Estabrooks et al., 2015), or prospective follow-up of patients over time where the 
last assessment before death was provided retrospectively (Brandt et al., 2006a, 
Hendriks et al., 2014, Klapwijk et al., 2014, Hendriks et al., 2015).
6.2.4 Assessment scales - validated in people with dementia 
Our main outcome measure in Papers 1 and 3 is the MOBID-2 Pain Scale. Initially,  
the MOBID Pain Scale was developed and validated with seven items (observation at 
rest, moving hands, arms, and legs, turning in bed, sitting on the bedside, and mouth 
care) in people with advanced dementia (Husebo et al., 2007). Internal consistency 
showed very good kappa agreement between raters, which increased to over 0.90 
after exclusion of the two items for observation and mouth care. Inter-rater reliability 
was also proven as good to very good. The further development of the MOBID Pain 
Scale to the MOBID-2 Pain Scale included assessment of pain that might be related 
to the musculoskeletal system (MOBID-2 part 1) and to the internal organs, head, and 
skin (MOBID-2 part 2) (Husebo et al., 2010). The MOBID-2 shows good to excellent 
validity and reliability (Husebo et al., 2010). Most relevant for our studies is the fact 
that the MOBID-2 Pain Scale has proven to be responsive to change after initiation of 
pain management, and thus is capable of assessing the effect of treatment during 
analgesic interventions of a cRCT (Husebo et al., 2014b).
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Other screening or outcome scales used in our papers are the MMSE, CDR, FAST, 
Barthel ADL Index, and PSMS. For screening purposes we used the MMSE scale 
that was developed and validated in people with dementia, and has a Norwegian 
version and comes with a variety of different settings (Folstein et al., 1975, Braekhus 
et al., 1992). The MMSE has shown a floor effect, which might lead to an increasing 
number of people classified with advanced dementia. In Paper 1, we used the MMSE 
to identify patients able to consent (Etchells et al., 1999). We assessed the level of 
dementia by CDR or FAST in all three papers: FAST was used in Paper 1, CDR in 
Paper 3, and both tools in Paper 2. The FAST is not validated in Norwegian but is 
used routinely for clinical and research purposes in the nursing home setting (Testad 
et al., 2010). The CDR is validated and widely used (Nygaard and Ruths, 2003, 
Selbaek et al., 2007).
In Paper 2, we included four different samples where three assessed cognitive 
function using CDR, and only the 2009 sample used the FAST. This might have 
introduced a different classification of patients, either that patients classified with 
dementia with CDR were not classified with dementia by FAST, or vice versa. 
The Barthel ADL Index has good validation in aged adults but not those with 
multiple diagnoses, needs, or dementia. It is also found to have a floor and ceiling 
effect. This is less of a concern in our population of frail persons with dementia, 
compared with the concern of not having an interval scale, overall Likert scale, or a 
clear interpretability scoring system (Sainsbury et al., 2005).
6.2.5 Assessment scales - not validated in people with dementia
In Paper 3, we included the ESAS, KPS, and the RAI-PC scales. These tools are used 
in people with dementia in general, although they are not validated for use in dying 
people with dementia. This means that the sensitivity and specificity in dying 
individuals with dementia is unknown, as is the validity and reliability in this setting. 
Despite these drawbacks, we selected these tools because they include a wide range 
of burdensome symptoms which might be present at the end of life.  
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To evaluate change in intensity scores over time and during treatment, it was further 
important to include scales with continued intensity measures because dichotomous 
registrations are not able to detect symptom intensity change. 
Although not investigated for validity and reliability in dying patients with dementia, 
the RAI-PC has been used in this population by others (Brandt et al., 2006a). The 
ESAS is used in people with dementia and validated for proxy-rating (Nekolaichuk et 
al., 1999a, Nekolaichuk et al., 1999b, Pautex et al., 2003, Yang et al., 2016).
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6.3 Discussion of the results
6.3.1 Pain and pain management associated with age, gender, and 
dementia 
Our three publications contribute novel and unique results that strengthen this thesis. 
In the following, I aim to discuss our approach as a whole, including different aspects 
such as age, gender, and dementia, and also pain and pain management across the 
studies.
Age Patients in our studies show a mean and median increase in age of two years 
from 2000 (median 85, range 65-101) and to the REDIC study (2012-2014) (median 
87, range 65-106), confirming the nursing home setting as increasingly a service for
the oldest old (Table 8). It also reflects our society’s ageing population. The 
increasing age over years has been observed by comparable studies in the nursing 
home setting (Ruths et al., 2013). People with dementia have a higher age compared 
with those  without dementia, in memory clinics, home care service, and in the 
nursing home (Vossius et al., 2015). Thus, increasing age may follow the rising 
proportion of persons with dementia in the latter context.
Gender Demonstrated in Table 8, the proportion of women is smaller at admission to 
a nursing home compared with the stable proportions seen over time in the samples of 
Papers 1 and 2. This suggests a higher survival rate in women after nursing home 
admission. Female gender and increased age were also associated with increased 
analgesic drug prescription (Paper 2). Baseline data by the REDIC study also 
confirmed a crude odds ratio association between analgesics and female gender 
(P=.040) but not between analgesics and age (P=.074).
Dementia The proportion of people with dementia has risen over the years from 76% 
in 2000 to 87% in 2012/2014, a development also reported by (Helvik et al., 2015).
This proportion is higher compared with home-dwelling people with dementia (42%)
(Wergeland et al., 2014).
Pain According to Table 8, we find that the prevalence of moderate to severe pain 
(MOBID-
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an increasing trend towards the day of imminent dying (65%) (Paper 3). This 
prevalence widely corresponds with results in Paper 1 (62%). In Paper 3, we also 
demonstrated that 46% of the patients (95% CI; 41-51) have moderate pain and 16% 
(95% CI; 13-21) have severe pain. The findings imply daily suffering for the general 
nursing home population. 
Comparable prevalence results are reported from Finland (57%), the Netherlands 
(43%), and Italy (32%) (Achterberg et al., 2010). Using the MDS as an outcome 
measure, the study found moderate to severe pain intensity in over 50% of cases in all 
of these countries. The proportions of moderate to severe pain found in our study are 
higher compared with outpatients with cancer diagnoses (23%) (Oosterling et al., 
2016) but comparable with patients hospitalised in the palliative care setting (83%) 
(Harada et al., 2016).
In Table 8 we show that in addition to the already mentioned results regarding age, 
gender, dementia, and pain intensity, the physical function and most painful locations 
shift over time from admission to death. Patients have less dependence upon 
admission compared with the average nursing home population found in Paper 1 and 
previous findings (Mjorud et al., 2014). Between admission and day of imminent 
death, the KPS unsurprisingly shows a change in mean from in need of medical 
assistance to very ill. 
The three most painful locations at admission correspond to the ones found in the 
average nursing home population (Paper 1): moving the legs, pelvis, and turning in 
bed. On the day of imminent death, care-staff report that moving the patients induces 
the most pain when turning, sitting up in bed, and moving the legs. On the day of 
death, sitting up in bed might be avoided, but turning in bed is considered to hurt the 
most, followed by pain from the pelvis and moving the legs.
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Pain management The analgesic drug prescription increases substantially (65%) 
over time in Norwegian nursing homes (Paper 2) and prescribing patterns seem to be  
associated with the presence of pain (P<.001) (Paper 3). However, this does not 
guarantee that the pain management is adapted individually to the patient’s pain level. 
Analgesic drug use in nursing homes does not correspond to the stable consumption 
in the general population and in home-dwelling people aged 75 years old and older 
(Fig. 5). However, it is encouraging to find an equal prescription independent from 
the level of dementia that is not in line with other recent findings (Tan et al., 2015).
We also find a continuous growth in analgesic drug prescriptions in persons with 
dementia, and not in persons without dementia. Thus, increased monitoring of 
Table 8: Demographic details, physical function, overall pain intensity and prevalence in study  
samples included in Papers 1 and 3 
 Paper 1 Paper 2 Paper 3 
Characteristics Pain-
BPSD  






Age, mean (SD) 85 (7) 84 (7) 86 (8) 86 (8)   
Gender, female % 74 70 71 64   
Dementia, % 87 76 83 87   
ADL function, Barthel 
mean (SD)§ 
8 (6)      
ADL function PSMS 
mean (SD)# 
   15 (5)   
Karnofsky (100-0)†    54 (30) 16 (10)  
MOBID-2 Smerteskala       
Hands, mean (SD) 0.9 (2.9)   0.4 (1.4) 1.3 (2.6) 0.6 (1.5) 
Arms, mean (SD) 1.7 (2.4)   1.0 (2.0) 1.9 (2.5) 1.0 (1.8) 
Legs, mean (SD) 2.3 (2.8)   1.3 (2.2) 2.9 (3.1) 1.4 (2.5) 
Turn, mean (SD) 2.0 (2.7)   1.2 (2.1) 3.6 (3.2) 2.6 (3.2) 
Sit, mean (SD) 1.8 (2.6)   1.1 (1.9) 3.0 (3.2) 0.9 (2.3) 
Head, mouth neck, mean 
(SD) 
1.2 (2.1)   0.6 (1.5) 2.0 (3.0) 0.9 (2.0) 
Heart, lung, chest, mean 
(SD) 
0.8 (1.7)   0.4 (1.2) 1.1 (2.2) 0.9 (2.0) 
Abdomen, mean (SD) 0.9 (1.8)   0.7 (1.6) 1.1 (2.1) 1.0 (1.9) 
Pelvis, genital organs, 
mean (SD) 
1.7 (2.6)   1.3 (2.3) 2.3 (2.7) 1.5 (2.3) 
Skin, mean (SD) 1.6 (2.4)   0.7 (1.7) 2.0 (3.0) 1.0 (2.2) 
Total score, mean (SD) 3.7 (2.6)   2.1 (2.1) 4.0 (3.0) 2.7 (2.8) 
Proportion pain 0-2, % 38   63 35 55 
Proportion pain 3-6, % 46   33 53 41 
Proportion pain 7-10, % 16   4 12 4 
§ADL scale (0-20): higher score equals better function 
#ADL scale (6-30): higher score equals more dependence 
†Higher score equals better function 
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treatment with association to age, gender, and level of dementia is needed. Further, 
the results of our studies underline the need for recommendations and educational 
packages for nursing home patients and people with dementia.
Figure 5. Total amount of prescribed analgesics (N02+M01) based on data from Paper 2 and the NorPD. 
GPN=General population of Norway
NHP=Nursing home population, Paper 2
Comparable trends are reported from the United Kingdom and Denmark (Zin et al., 
2014, Jensen-Dahm et al., 2014). In Denmark a worrying upswing in opioid use finds 
that up to 38% of people with dementia are treated with opioids, and 28% with strong
opioids in Danish nursing homes (Jensen-Dahm et al., 2014). Prescribing patterns are 
mainly based on long acting transdermal applications of buprenorphine and fentanyl 
patches. There are only very few studies investigating the effects and side-effects of 
opioid use in elderly people with dementia (Habiger et al., 2016), and our own
experiences recommend a more than careful use because of severe side-effects such 
as drowsiness, impaired cognition, loss of appetite, and increased balance 
disturbances. 
6.3.2 Pain treatment effect – does it help, clinically?
Paper 1 reports one of the first studies to investigate the effect of pain management 
on pain intensity in people with dementia. These secondary analyses of a larger cRCT
are based on two “assumptions”: a SPTP and the efficacy assessment outcome 
measure MOBID-2 Pain Scale. Until now, clinical studies have been hampered by the 
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after the treatment has been initiated. Thus, the results of our study may also be 
questionable.  
We developed the SPTP based on clinical guidelines for older adults that have been 
published by the American Geriatrics Society in 1998 with repeated revisions in 2002 
and 2009 (AGS-Panel, 1998, AGS-Panel, 2002, AGS-Panel, 2009). Although these 
guidelines are not specifically formulated for people with dementia, they highlight 
careful titration of the drugs and combination of two or more drugs with 
complementary mechanisms to improve pain relief with less hepatic and kidney 
toxicity and side effects. Following these recommendations, we also used the 
antiepileptic pregabalin in people suggested to be in neuropathic pain caused by, for 
instance, stroke or diabetes. Although we only included 12 participants, our data 
indicate a significant benefit especially important in light of the large group of people 
with dementia suggested to suffer from neuropathic pain associated with white matter 
lesions after stroke (Scherder et al., 2003a). To our knowledge, this is the first pain 
study including an antiepileptic drug as pain treatment in people with dementia.
The largest group of participants in the intervention group of Paper 1 was treated with 
paracetamol. Such treatment is well tolerated and only 2 of the 120 patients left the 
study following their families’ wishes. Paracetamol seems to be effective and well 
tolerated, and can thus be recommended as a first-line medication to treat pain in 
people with dementia. Although we did not find an overall effect of pain treatment on 
ADL function, the isolated group of “paracetamol receivers” demonstrated a 
significant improvement in their activities (P=0.04). These results support earlier 
suggestions that individual pain treatment with paracetamol may improve physical 
function and activities in daily living (Chibnall et al., 2005).
Interestingly, participants in the intervention group demonstrated a significant 
worsening of pain intensity when analgesics were discontinued in the wash-out
period. Contextual evidence has also been suggested by other analyses of this cRCT 
demonstrating the efficacy of treating pain on behavioural disturbances such as 
agitation, depression, apathy, and sleep and eating disturbances in people with 
dementia (Husebo et al., 2011, Husebo et al., 2014a). To conclude, findings 
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evidentially indicate the importance of immediate and individual pain management in 
people with dementia based on clinical appropriateness.
The other important “assumption” in Paper 1 has been the use of the primary outcome 
measure MOBID-2 Pain Scale. The latest version of the AGS Panel on Persistent 
Pain in Older Persons guidelines (2009) recommends the use of a validated pain 
assessment instrument (AGS-Panel, 2009). However, recommendations do not 
discuss the importance of the measurement property: responsiveness. In people with 
dementia, self-reported pain and change in pain intensity is invalid. Thus, the pain 
state has to be evaluated by a proxy-rater who uses a validated observational pain 
tool. To improve the treatment, this tool has to be practical and responsive.  In light 
of this, the MOBID-2 Pain Scale is currently the only tool tested for reliability, 
validity, and responsiveness to change. This is of key importance and makes the 
MOBID-2 Pain Scale a recommendable tool to assess the efficacy of pain treatment 
interventions in RCT studies.
6.3.2 Different end-of-life trajectories 
In Paper 3, we find that 25% of the patients admitted to a nursing home died within 
one year of admission. Pneumonia, heart failure, and dementia were the main 
underlying causes of death, and these results are supported by others who found that
survival is reduced in persons with dementia by pneumonia, febrile episodes, and 
eating problems (Mitchell et al., 2009).
Previous studies have discussed the differences in the end-of-life trajectories in 
patients with cancer diagnoses, heart and lung diseases, and long-term illnesses
(Harris, 2007, Murray et al., 2005). The fluctuating course of dementia may be 
prolonged over many years and characterised by multiple diseases or co-morbidities 
(Murtagh et al., 2004). This is in contrast to cancer, which follows a slower decline 
initially, but then shows a rapid decline near the end. This imposes a better planning 
for the last stage of life, as early and accurate identification along with the trajectory 
are more predictable (Murray et al., 2005).
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6.3.4 How to predict the day of imminent dying?
In our study (Paper 3), almost 40% of the patients were not identified in advance as 
dying by their primary caregiver. This has important consequences because people 
not recognised to be dying do not receive the necessary attention, communication, 
and treatment. On the other hand, those identified as imminently dying (61%) had 
significant fatigue and poor appetite. These symptoms were also highlighted by a 
Dutch nursing home study including 516 patients at the end of life (Brandt et al., 
2005a). The responsible physicians found little fluid (43%) and nutrition intake 
(25%), fatigue (32%), and dyspnoea (18%) to be indicators for reduced survival (less 
than six weeks) (Brandt et al., 2005a). This study also demonstrated that 93% of 
patients could be identified when they had less than one week to live (Brandt et al.,
2006b). Important differences in relation to our results may be caused by the 
challenge to make a reflected team-decision about the day of imminent dying and 
then to call the research nurse on that day.  
Symptoms of pain, dyspnoea, or agitation were not associated with the day of 
imminent dying in our study. This is interesting because symptoms of fatigue and 
reduced appetite alone do not explain the start of medical treatment with morphine, 
benzodiazepine, or anticholinergics. Pneumonia and heart failure at the end of life 
may lead to dyspnoea and pain. However, we are worried about the fact that staff 
may not be able to recognise and interpret related life-limiting symptoms.    
6.3.5 Symptom severity at the day of imminent dying
As stated, we use proxy-rated tools which might influence the symptom proportion 
and severity (Harris, 2007). This strengthens the requirement of the tools that must 
contain relevant symptoms for the patient group and validated for proxy-rating.
Increased responsibility of care should also be emphasised in staff training on 
symptom assessment and knowledge of the tools. To exemplify, when we investigate 
pain and dyspnoea at admission in all the 691 persons included, we find 45% of the 
patients to have pain and 22% to have dyspnoea, which is lower than comparable 
investigations (Hendriks et al., 2015). Hendriks and colleagues (2015) assessed all 
symptoms on a dichotomous scale of present or not, and find the proportional 
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prevalence of agitation to be 57%, pain 52%, and dyspnoea 19% at admission. In our 
study we did not investigate agitation using the ESAS but with the neuropsychiatric
inventory, and found that 11% had agitation, which is substantially lower compared 
with the almost 60% found by Hendriks and colleagues (Hendriks et al., 2015).  Few 
studies offer the comprehensive list of symptoms that we provide with an intensity 
score. However, we find that our results are more in line with studies who do use the 
ESAS tool, although we use a severity of 3 and they use a cut-off at 6 (Brandt et al., 
2006a).
Although national guidelines for dementia increasingly also focus on end-of-life care, 
there is a systematic lack of prognostication and concrete suggestions on how to 
provide comfort to dying elderly people (Nakanishi et al., 2015). In the following 
table 9 below, we mention some typical differences between end-of-life care for 
cancer patients compared with people with dementia. 
Table 9. End-of-life care comparing persons dying from cancer and persons dying from dementia 
Cancer Dementia
Predictable trajectory, where prognostication 
and recognition of the last days are possible
Fluctuating trajectory, comorbidities, and recurrent 
episodes of decline in function followed by 
improvement
Clear when to plan and for what scenario Planning must be made well in advance
Advance care planning can be provided
because the trajectory is clear
Advance care planning is complicated
Clear care goals can be provided ahead Care goals shift
Self-report is often possible Proxy-rating is needed
Well validated assessment tools Lack of validated tools assessing severity
Implementation of care and pharmacological 
treatment and effect is well documented, 
providing comfort prediction
Unclear pharmacological effect, very individualised, and 
with many comorbidities
Enhanced communication with patients and 
family
Person-centred care possible, although communication 
with person and care givers often complex
Well known what symptoms to assess Symptoms less clear
Staff competence is adjusted to patient need Staff competence often low
Palliative teams are cross-professional and 
easy to reach
Palliative competence is less implemented and 
problematic to reach
Nutritional efforts can be planned  Low effect and use of feeding tubes
Hospital admissions are planned Hospital admissions are acute and unplanned
Stopping burdensome interventions and
hospital admissions
Often many burdensome and unrequired interventions 
like transferals, oxygen, fluid, and feeding tubes
Spiritual and psychological support possible 
to assess efficiency 
Spiritual and psychological support not often provided
Education programmes implemented Few education programmes available
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6.3.6 Symptom severity and management on the day of death
We find that the proportion of persons experiencing moderate and severe symptom 
intensity declines for most symptoms over time. However, this does not refute a high 
symptom burden on the day of death. In addition, respiratory symptoms like 
dyspnoea and death rattle increase. Considering the increase in symptom 
management, this is worrying. 
The symptom severity we find regarding pain (46%) and agitation (3%) are lower 
compared with the findings of Hendriks et al. (2015), where physicians reflected back
on the last week of life (Hendriks et al., 2015).  The severity of dyspnoea that we find 
in our study (53%) is comparable with the 52% that Hendriks et al. (2015) found in 
their study. The severity of agitation (3%) and delirium (3%) that we find in our 
Paper 3 is substantially lower than previous studies (Hall et al., 2002, Hendriks et al., 
2014, Hendriks et al., 2015). Hendriks and colleagues (2014, 2015) find that 35% of 
patients are agitated during the last week of life, and Hall and colleagues (2002) find 
that 30% experience delirium (Hall et al., 2002, Hendriks et al., 2014, Hendriks et al., 
2015). It might be questioned if agitation and delirium are two distinct symptoms, or 
if both cover delirium. We added the symptom burden of the two and found that the 
symptom intensity lessened towards the day of death (28 to 19%, P<0.001). The
identification of delirium is complex and in need of enhanced focus and improved 
tools. We did not include a specific instrument for delirium like the Confusion 
Assessment Method, which might have introduced an under-detection of delirium. 
Future research would benefit from designing and testing a tool to detect delirium in 
dying patients with dementia. 
The suitability of assessment tools will affect the proportion of symptoms found, and
this was the case for a small Dutch study investigating symptom severity and 
management in 24 nursing home patients with dementia during the last week of their 
life (Klapwijk et al., 2014). The MSSE was more sensitive and detected a higher 
proportion of pain (36%) compared with the EOLD-CAD tool (15%) (Klapwijk et al., 
2014).
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The provision of administered pharmacological treatment found by us is lower 
compared with previous findings of prescribed drugs during the last 24 hours of life 
(Jansen et al., 2014). This difference between prescribed and administered drugs 
might occur because the anticipatory drugs are not tailored to the person’s symptoms 
and needs. However, there can also be a very rapid change in the individual needs of 
the patients for the physicians to change the treatment plan.
Opioids are also provided to nursing home patients to relieve dyspnoea (Hall et al., 
2002, Hendriks et al., 2014, Hendriks et al., 2015). Therefore, it was unexpected that
our Paper 3 did not find opioids associated with the amelioration of dyspnoea. There 
are several underlying causes for dyspnoea like congestive heart failure, fever, and 
lung oedema. Management will need to target the underlying cause of the symptom 
for better symptom relief.  We found an effect of opioids on death rattle, which raises 
the question of whether the caregivers have misclassified these symptoms. 
The most current evidence base is provided by the NICE guideline “Care of dying 
adults in the last days of life” in the United Kingdom. Pharmacological intervention 
studies comprised the management of pain, breathlessness, and noisy secretion. The 
evidence for pharmacological interventions was rated as either low or of very low 
quality in most of the studies, and most studies included only cancer patients 
(NCCMH, 2015). This review did not find any studies including persons with 
dementia solely. Thus, this leaves a considerable need for studies investigating the 




External validity or generalisability discusses the ability to refer the study results to 
other clinical circumstances, both national and international (Akobeng, 2008). We 
suggest that our results are representative for most of the Norwegian nursing home 
settings where about 50% of the patients have mixed dementia (Husebo et al., 2008).
We expect that the stepwise protocol of treating pain, used in Paper 1, has the ability 
to impact prescribing routines and pain management in nursing home patients. 
Hopefully it also has a broad impact on patients and care givers, and will guide new 
research.  
For Paper 2, the external validity is given in a national perspective by a broad 
inclusion of the high number of nursing homes. The follow-up of the same cohorts 
over time could be a future perspective.  As we performed analyses on the 2004 and 
2011 sample, to adjust for covariates, we have ensured representativeness to the 
general nursing home patient. Importantly, our study samples do not differ from other 
international nursing home samples, and thus the results can be applied to them. 
Small and large nursing homes in both cities and rural areas have been included, 
which enhances the generalisability to the general nursing home population.
Extrapolating results from Paper 3 to all dying Norwegian nursing home patients is 
more critical. Despite the inclusion of a high number of nursing homes (N=47) and 
number of participants (N=691), we only followed 134 patients to the day of death. 
Although this group of patients is larger than comparable samples, results cannot be 
generalised without further discussion. To our knowledge, this is the first study which 
follows dying people prospectively, as close as possible. Results have to be proven in 
national and international studies, followed by intervention studies to improve the 
situation for dying elderly people. Correct symptom assessment and management is 
important to ensure a dignified death. Our findings are of importance for future dying 
persons in nursing homes, their loved ones, and the staff caring for them. 
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6.5 Ethical considerations
All paragraphs of the declaration of Helsinki of June 1964 by the World Medical 
Association are vital for all research. For our studies there are some very important 
points to discuss: informed consent, ethic committees, vulnerable groups, and 
registration and dissemination of results (WMA, 2016). Four principles of medical 
ethics have been suggested by Beauchamp and Childress to unite deontological and 
teleological ethical theories (Beauchamp and Childress, 2001): autonomy vs. 
paternalism, beneficence, non-maleficence, and justice. 
All studies included in this thesis have been approved by the regional ethical 
committees. Paper 1 also had approval from and was continuously controlled by the 
Norwegian Medicines Agency. The BPSD-pain and the REDIC study were registered 
at Clinical Trials.gov before the recruitment of study participants and had clear plans 
for dissemination of the results. Collecting data also obliges the researchers to use 
these data in accordance to a priori hypotheses. All researchers are obliged to use 
already collected data when possible, instead of performing new studies. These 
responsibilities have been well guarded by the included studies. 
Including vulnerable individuals with the possibilities of experiencing additional 
suffering should be balanced with paragraph 13 of the declaration of Helsinki, stating 
that underrepresented groups should be provided access as participants in medical 
research. Of course, only as long as the possible harms are minimised and justified by 
therapeutic value to the persons participating. Excluding patients with dementia from 
medical studies might prevent them as a group from optimised treatment and best 
practice. According to the declaration of Helsinki, the use of placebo or no 
intervention is acceptable where no best practice exists. This is very relevant for our 
Paper 1 as we randomised individuals in clusters to intervention and used current 
practice as control. We did not remove any treatment. This means that the control 
group’s daily care was expected to be the current best practice, also when we 
discontinued study drugs in the wash-out period. On the one hand, it can be argued 
that providing analgesic treatment for frail elderly adults might introduce harmful 
side-effects and cause maleficence, whereas on the other hand it can also be argued 
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that keeping persons from possible beneficial treatment over 12 weeks is both 
harmful and unjust.  
In the Nuremberg code, of which the declaration of Helsinki originates, the first 
paragraph clearly states that participation in research is possible by voluntary 
informed consent (Nuremberg, 1949). In the current version of the declaration, seven 
paragraphs outline consent and in the 30th paragraph the declaration opens for 
involving persons incapable of giving informed consent by pursuing consent from the 
persons legally authorised as their representatives. 
In Paper 2, study samples from 2000, 2004, and 2011 patients and the legally 
authorised representative for the person received information, and they were able to 
withdraw before or during the study. In the BPSD-pain and REDIC study the MMSE, 
was used as guidance (Etchells et al., 1999). The MMSE is merely a staging tool for 
cognitive capacity, but the most commonly used aid to evaluate ability to give 
informed consent. As suggested by the declaration of Helsinki, the ethic committees, 
and Norwegian legislation, consent can be obtained from authorised legal 
representatives (proxy-informed consent) when the individuals are unable to provide 
their own written consent. Our consideration was to use the outlined consent 
procedure: provide sufficient written and verbal information in a form understandable 
to the individual, provide sufficient time to understand the information, test to see if 
the information was understood, and ensure that the individual could reflect upon and 
judge the information (Warner and Nomani, 2008).
Longitudinal prospective studies provide the opportunity to approach patients to 
obtain consent at admission for observations also at the end of life. Such studies are 
very demanding and need substantial resources, however if not provided then such 
studies might be the reason why we lack clinical information and best practice today.
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7. Conclusions
In this thesis, I highlighted various aspects of pain and symptom management in 
nursing home patients, from the efficacy of individual pain treatment, via prescription 
trends, to symptom severity and usefulness of pharmacological treatment in the last 
days and hours of life. 
In Paper 1, our well-powered and robust study found that a SPTP significantly 
improved pain intensity in nursing home patients with moderate to severe dementia 
and behavioural symptoms. Pain treatment with paracetamol improved ADL. Our 
findings call for improved staff competence and pain assessment as a standardised 
approach for pain management. 
In Paper 2, we found an overall increase in analgesic prescription in 65% of the 
participants from 2000-2011 in Norwegian nursing homes. The use of paracetamol 
and opioids increased by 113% and 118%, respectively. However, strong opioids 
showed the largest increase as they increased almost nine-fold from 2000 to 2011. In 
2011, we did not find that the analgesic drug prescription differed between persons 
with and without dementia. Advanced age and female gender were associated with 
prescription of any analgesic agent.  
Evolving from our Paper 3 is the identification of imminent dying by observing poor 
appetite and fatigue, which increased prediction accuracy to 61%. Further, we found 
that pain and burdensome symptoms ameliorated from the day patients were 
perceived to be dying until the day of death, except for respiratory symptoms that 
increased. Despite intensified pharmacological intervention, the symptom burden was 
still high on the day of death in nursing home patients. 
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7.1 Implications and future perspectives
This thesis arose from the Centre for Elderly and Nursing Home Medicine, 
Department of Global Public Health and Primary Care, University of Bergen, and has 
its strategic aims spread across the four pillars of implementation, research, 
education, and national and international collaboration. 
Implementations that may arise from this thesis are systematic assessment of pain and 
burdensome symptoms from admission to a nursing home, over a nursing home stay, 
and to the last days and hours of life. Our SPTP, designed to lessen pain intensity in 
nursing home patients and to ameliorate burdensome symptoms at the end of life, can 
be implemented and follow the provided assessments. This thesis finds support for 
the use of pharmacological treatment in dying nursing home patients and urges their 
implementation in this setting. We were not able to relate our prescription data to 
patients’ pain intensity and it is important to do so ahead, therefore a nursing home 
registry containing prescription data as well as clinical symptoms is needed.  
Studies succeeding our investigations are continuing studies of the efficacy on 
different analgesic agents in placebo-controlled studies, including persons with 
dementia and pain. The interaction of pain intensity, analgesic agents, and physical 
function is barely investigated, but based on our findings it is of utmost importance to 
explore this in epidemiological studies, in trajectory studies following persons over 
time, and in RCTs. The impact of the discontinuation of analgesic agents on clinical 
outcomes like pain intensity, behaviour, and mood is beneficial for patients to explore 
in a RCT trial.
Our results show a substantially increased prescription trend of analgesic agents, and 
that for persons with dementia the trend continues. Our period of investigation was 
limited to one decade. In future studies, the analgesic prescribing patterns should be 
followed over a longer period of time to confirm the increase as a trend. Further, the 
prescribing patterns for patients must be investigated also in home-dwelling older 
adults with and without dementia.
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This thesis calls for educational packages for nursing home and home-care service 
staff. Complex interventions and education are needed to be developed in robust 
research studies and implemented in nursing homes and home-care services. This 
responsibility must be taken seriously by all educators of healthcare staff, and thereby 
improve care for and shift focus onto people with dementia, who are the fastest 
growing group of persons in need of quality care. 
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Background: Pain is frequent and distressing in people with dementia,
but no randomized controlled trials have evaluated the effect of analgesic
treatment on pain intensity as a key outcome.
Methods: Three hundred fifty-two people with dementia and significant
agitation from 60 nursing home units were included in this study. These
units, representing 18 nursing homes in western Norway, were
randomized to a stepwise protocol of treating pain (SPTP) or usual care.
The SPTP group received acetaminophen, morphine, buprenorphine
transdermal patch and pregabalin for 8 weeks, with a 4-week washout
period. Medications were governed by the SPTP and each participant’s
existing prescriptions. We obtained pain intensity scores from 327 patients
(intervention n = 164, control n = 163) at five time points assessed by the
primary outcome measure, Mobilization-Observation-Behaviour-
Intensity-Dementia-2 (MOBID-2) Pain Scale. The secondary outcome was
activities of daily living (ADL). We used a linear intercept mixed model in
a two-way repeated measures configuration to assess change over time
and between groups.
Results: The SPTP conferred significant benefit in MOBID-2 scores
compared with the control group [average treatment effect (ATE) −1.388;
p < 0.001] at week 8, and MOBID-2 scores worsened during the washout
period (ATE = −0.701; p = 0.022). Examining different analgesic
treatments, benefit was conferred to patients receiving acetaminophen
compared with the controls at week 2 (ATE = −0.663; p = 0.010),
continuing to increase until week 8 (ATE = −1.297; p < 0.001). Although
there were no overall improvements in ADL, an increase was seen in the
group receiving acetaminophen (ATE = +1.0; p = 0.022).
Conclusion: Pain medication significantly improved pain in the
intervention group, with indications that acetaminophen also improved
ADL function.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
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1. Introduction
Dementia affects approximately 10 million people in
Europe, and this is expected to double every 20 years
as the population ages (Kalaria et al., 2008). One-third
of people with dementia reside in nursing homes
(NHs). In addition to the distress experienced by these
individuals as a result of their condition, many also
experience pain (Achterberg et al., 2007). The precise
prevalence of pain is unclear, but estimates indicate
that up to 80% of NH patients are in acute or chronic
pain (Husebo et al., 2008; Achterberg et al., 2010,
2013). The majority experience persistent pain lasting
6 months or longer (Pickering et al., 2006). The most
common types of pain are musculoskeletal, such as
arthritis, or neuropathic pain as result of diabetes or
stroke (Scherder and Plooij, 2012). Despite the high
prevalence of pain in these individuals, assessment is
difficult due to the loss of cognitive and communica-
tive abilities.
Pain is distressing for the individual who experi-
ences it and often correlates with key symptoms,
ranging from problems with coordination and
memory to changes in personality and behaviour. This
can also lead to an increased risk of falls (Deandrea
et al., 2010; Huang et al., 2012), behavioural and psy-
chological symptoms of dementia (BPSD) such as agi-
tation and aggression (Hurley et al., 1992; Lin et al.,
2011; Ahn and Horgas, 2013; Husebo et al., 2013),
and depression (Cohen-Mansfield and Taylor, 1998).
In addition, undertreated pain affects social interac-
tion, provokes sleep disturbances and reduces quality
of life (Giron et al., 2002; Cipher and Clifford, 2004;
Cordner et al., 2010). Furthermore, people experienc-
ing BPSD due to pain may be inappropriately pre-
scribed anti-psychotic medication, which can be
harmful, rather than analgesia (Corbett et al.,
2012a,b).
A limitation in the existing literature is the lack of
large randomized controlled trial (RCT) studies with
pain intensity as the main outcome (Corbett et al.,
2012a,b). To date, no large-scale pain intervention
studies have focused upon improvement of pain
intensity as a key outcome (Lorenz et al., 2008). Most
studies, including four RCTs, have utilized measures of
BPSD, mood or activities of daily living (ADL) as proxy
measures of pain (Manfredi et al., 2003; Buffum et al.,
2004; Chibnall et al., 2005; Kovach et al., 2006). All
RCTs were performed in the NH setting and with aged
patients investigating the effect of pain medication on
agitation. However, none of these trials included a
measure of pain or a systematic pain management
protocol.
The absence of data regarding the impact of pain
intensity is, in part, due to the challenge of accurately
identifying pain robustly. We recently developed and
tested the Mobilization-Observation-Behaviour-
Intensity-Dementia-2 (MOBID-2) Pain Scale for use in
NH patients with dementia (Husebo et al., 2010). This
article reports secondary analyses of an 8-week RCT
with follow-up assessment after a 4-week washout
period to investigate the effect of pain treatment on
pain intensity in NH patients with dementia, assessed
by the MOBID-2 Pain Scale.
2. Methods
The trial is registered at ClinicalTrials.gov (number
NCT01021696) and at the Norwegian Medicines Agency
(EudraCT nr: 2008-007490-20). Ethical approval was
obtained in accordance with local law, by the Regional Com-
mittee for Medical Ethics, Western Norway (REK-Vest
248.08) and by the authorized Institutional Review Board of
each participating institution.
2.1 Study design
This study was an 8-week RCT comparing the effect of the
stepwise protocol of treating pain (SPTP) intervention with
control in people with dementia living in Norwegian NHs.
The trial included a 4-week washout period with additional
follow-up at 12 weeks. The recruitment strategy of 18 NHs,
patient samples and full study design has been described in
our previous publication (Husebo et al., 2011).
What’s already known about this topic?
• Many people with dementia experience pain
regularly, but are not able to communicate this to
their carers or physicians due to the limited self-
report capacity inherent in the symptomatology
of dementia.
• Few studies have investigated the direct effect of
pain treatment on pain intensity in patients suf-
fering from dementia, with previous studies
using proxy measures of behavioural symptoms.
What does this study add?
• A stepwise protocol to treat pain in nursing
home residents with moderate to severe demen-
tia significantly reduced pain intensity.
• Pain treatment by acetaminophen improved
activities of daily living.
• There is an urgent need for a standardized
approach to assessment and treatment of pain for
nursing home residents with dementia.
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2.2 Eligibility criteria
Participants included in this study were people aged 65 years
and older residing in a NH for at least 4 weeks. Inclusion
criteria were a diagnosis of Alzheimer’s disease or other
dementias according to Diagnostic and Statistical Manual of
Mental Disorders, a Functional Assessment Staging score >4
(Reisberg et al., 1982) and clinically relevant behavioural
disturbances defined as Cohen Mansfield Agitation Inven-
tory score ≥39 (i.e., at least 1-week history of clinically sig-
nificant agitation) (Cohen-Mansfield et al., 1989; Finkel
et al., 1992). Only patients with moderate or severe demen-
tia, defined as a score of <20 on the Mini-Mental State
Examination scale (MMSE) (range 0–30), were included
(Folstein et al., 1975). Residents were included independent
of painful diagnoses, presumed pain or ongoing pain treat-
ment. Residents were excluded if they had an expected sur-
vival of less than 6 months, severe psychosis or allergy to any
of the study drugs. Written informed consent included a
description of the study design, benefit and possible side
effects of the trial. We took into consideration that even
individuals with mild cognitive impairment might have
impaired capacity to consent to research (Warner and
Nomani, 2008; Ayalon, 2009) and obtained informed
consent from all patients and all surrogates/caregivers or the
authorized legal representatives. Caregivers also gave
consent to participate as informants.
2.3 Intervention
The SPTP followed the latest recommendations of the Ameri-
can Geriatric Society (AGS) Panel for pharmacological man-
agement of persistent pain in older adults (AGS Panel on
Persistent Pain in Older Persons, 2009) and is described in
our previous publication (Husebo et al., 2011). All patients
assigned to the treatment group were investigated individu-
ally by the responsible team, which consisted of the NH
physician, the patient’s primary caregiver, a pain therapist
(B.S.H.) and a research assistant (R.K.S.). After a thorough
discussion, the team agreed on the most appropriate pain
medication and dosage according to the standardized SPTP
protocol. Depending upon their existing prescribed pain
treatment, patients received titrated analgesia in a stepped
approach. Patients previously receiving no or low dose of
acetaminophen received acetaminophen orally (3 g/day)
(step 1). If they already had a prescription of acetaminophen,
they were adjusted to either extended release morphine
orally (10 or 20 mg/day) (step 2) or buprenorphine trans-
dermal patch (5 μg or 10 μg/h for 7 days) (step 3). If patients
were already receiving step 3 medications and had neuro-
pathic pain, they received pregabalin orally (25, 50 or 75 mg/
day) (step 4), using a fixed dose regime throughout the
8-week treatment period. Most cases at steps 2–4 received
combination therapy with different analgesics. Patients with
swallowing difficulties started at step 3. Medication was
offered at breakfast, lunch and dinner (approximately 08:00,
13:00 and 18:00 h), respectively. In patients who were not
able to tolerate this treatment, the dosage was reduced or the
patient was withdrawn from the study and treated as clini-
cally appropriate. The treating physicians were instructed to
keep prescriptions and doses of analgesics unchanged in the
control group.
2.4 Outcome measures
Outcome measures were completed at baseline, 2, 4, 8 and
12 weeks. The MOBID-2 Pain Scale was used to assess pain
intensity in the participants. MOBID-2 is a two-part staff-
administered observational pain behaviour instrument,
developed and tested in NH patients with advanced demen-
tia (Husebo et al., 2010). Assessment of pain intensity is
based upon the patient’s immediate pain behaviour such as
vocalization, facial expression and use of defensive body
positions. MOBID-2 part 1 assesses pain related to the mus-
culoskeletal system in connection with standardized, guided
movements during morning care (five items). MOBID-2 part
2 assesses pain that might originate from internal organs,
head and skin and is monitored over time (five items). After
registration of pain behaviour, observations are inferred to
pain intensity using a 10-point numerical rating scale (NRS).
Caregivers are encouraged to judge whether the observed
behaviour is related to pain or to dementia and psychiatric
disorders. Finally, an independent overall pain intensity
score is completed, again using a NRS. Previous studies on
the psychometric properties of MOBID and MOBID-2 pain
scale have showed that the inter- and intra-rater and test–
retest reliability of the scale is very good to excellent, with
Intra Class Correlations ranging from 0.80 to 0.94 and from
0.60 to 0.94, respectively (Husebo et al., 2007, 2009, 2010).
Internal consistency was highly satisfactory with Cronbach’s
α ranging from 0.82 to 0.84. Face, construct and concurrent
validity was good and it has shown good feasibility in clinical
practice (Husebo et al., 2007, 2009). Indications were pro-
vided that MOBID-2 is responsive to a decrease in pain
intensity after pain treatment (Husebo et al., 2014).
An additional outcome measure was physical function
assessed with the Barthel ADL index (range 0–20), in which
higher values indicate higher levels of activities of daily func-
tioning and independence (Mahoney and Barthel, 1965).
Safety and tolerability were monitored at each assessment,
and all adverse events and vital signs were recorded.
2.5 Randomization and blinding
Randomization was executed using Stata version 8 (Stata-
Corp LP, College Station, TX, USA). To eliminate selection
bias at institution level, we defined a cluster as a single
independent NH unit (with no crossover of staff), and ran-
domized these units. Thus, patients in each cluster were
randomly assigned to receive SPTP in the intervention group
or continue with treatment as usual (control group), using a
computer-generated list of random numbers for allocation of
the clusters by the study statistician. During enrolment, two
trained research assistants interviewed the patients’ primary
Pain treatment in dementia R.K. Sandvik et al.
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caregivers. The outcome measures and drug prescriptions
were reviewed by a consultant for old age psychiatry (D.A.),
an anaesthetist and pain therapist (B.S.H.), one of the
research assistants (R.S.) and a senior member of staff,
usually a general practitioner from the NH after completion
of the enrolment process and prior to randomization.
Researchers and nurses with responsibility for carrying out
the intervention did not participate in data collection.
Research assistants and staff members who collected the data
were blinded to group allocation and type of intervention
during the study period. The staff were instructed not to
discuss management procedures.
2.6 Data analysis
The mean, standard deviation (SD) and range were calcu-
lated for participant demographics. We described the groups
at baseline with two-sample independent t-tests for normally
distributed continuous variables, chi-square test for categori-
cal variables and Mann–Whitney test for continuous vari-
ables with non-normal distribution. Differences in mean and
standard error (SE) of the mean MOBID-2 Pain Scale and
ADL scores over time between treatment groups were esti-
mated with linear random intercept quantile mixed-effect
models. Mixed model regression modelled with linear
random intercept permits multiple measurements per person
over time, irregular intervals between measurements and
allows for incomplete data on assumption that data are
missing at random (Verbeke and Molenberghs, 2000). We
included the NH units as a nestling level in our analysis.
Statistical analyses were conducted with IBM SPSS Statistics
for Windows version 21.0 (IBM Corp, Armonk, NY, USA)
and R version 3.0.0 (The R Foundation for Statistical Com-
puting, Vienna, Austria) and package nlme-3.1-109.
3. Results
3.1 Cohort characteristics
Four hundred twenty eligible patients were identified,
of whom 352 were included and cluster randomized to
control (n = 177, cluster n = 27) or intervention
groups (n = 175, cluster n = 33). In total, 327 partici-
pants had a MOBID-2 pain score at baseline and were
included in this stepwise protocol of treating pain
analyses (control n = 163, intervention n = 164).
Dropout rate was equally distributed between groups.
The detailed flow of participants through this study is
summarized in Fig. 1. Demographic data for the
cohort are presented in Table 1. No differences were
found between the groups at baseline.
Pain diagnoses and intensity were distributed
equally between control and intervention groups at
baseline. Over 70% of participants had one or more
diagnoses of pain (Table 1). Inferred pain intensity
greater than zero was observed in over 80% of the
patients (n = 282), and intensity of 3 or higher was
seen in over 60% (n = 203). MOBID-2 part 1 assess-
ment indicated that the majority of pain resulted from
guided movements of the legs and from turning over
in bed. MOBID-2 part 2 showed the most frequently
affected sites were the pelvis/genital organs and skin
(Table 2). We found no differences in pain intensity
between groups with different levels of dementia
assessed by MMSE (p = 0.196). Participants who were
assumed to have neuropathic pain and were treated
with pregabalin had significantly higher pain scores
than controls and the other treatment groups at base-
line (MOBID-2 pain score 6.1; p = 0.001). Pain inten-
sity did not differ between the other groups at
baseline: control group (MOBID-2 pain score 3.65),
acetaminophen group (mean 3.53; p = 0.674) and
morphine group (extended release morphine and
buprenorphine) (mean 3.97; p = 0.469).
3.2 SPTP treatment allocation
In the intervention group, 62.8% of the patients
(n = 103) started administration of acetaminophen
(step 1) (i.e., acetaminophen 3 g/day), and 5.5%
(n = 9) had an existing prescription of lower dose acet-
aminophen increased to a higher dosage. Thus, 112
patients received acetaminophen only. Three patients
received step 2, all three had acetaminophen as well
(two started with extended release morphine, and in
one participant the primary prescription was
adjusted). Step 3, the buprenorphine transdermal
patch, was administered to 29 patients (17.7%), and
the buprenorphine dosage was increased in an addi-
tional eight participants. In total, 37 participants were
treated with buprenorphine transdermal patch, of
whom 9 received the patch alone, with no other medi-
cation, due to swallowing issues. Twelve participants
were treated with step 4, pregabalin, all of whom also
received acetaminophen and the buprenorphine
patch. All other patients (n = 28) had a combination of
acetaminophen and buprenorphine.
3.3 Outcome measures
Analysis of pain intensity outcomes showed a signifi-
cant improvement in the treatment group compared
to controls in weeks 2 [average treatment effect (ATE)
−0.703; SE 0.24; p = 0.004] and 8 (ATE = −1.393; SE
0.3; p < 0.001) (Table 2). This improvement was seen
in MOBID-2 overall pain intensity (Fig. 2) in addition
to specific items assessing musculoskeletal pain
(Fig. 3) and pain related to internal organs, head and
R.K. Sandvik et al. Pain treatment in dementia
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skin (Fig. 4). A sub-analysis of the participants who
had a score of 3 or greater on the MOBID-2 Pain Scale
at baseline also showed significant benefit in the treat-
ment group compared with control (ATE = −1.739;
p < 0.001) in week 8, with an average difference in
pain reduction of 50% from baseline to week 8 in the
treatment group.
An analysis of the efficacy of different treatment
approaches within the treatment group is presented in
Fig. 5 and shows that participants treated with acet-
aminophen had significant improvement of pain at all
time points, at week 2, 4 and 8, respectively
(ATE = −0.67, p = 0.010; ATE = −0.92, p < 0.001;
ATE = −1.30, p < 0.001). Patients treated with
extended release morphine or buprenorphine trans-
dermal patch also showed a significant decrease in
MOBID-2 total scores, but not before week 8
(ATE = −1.14; p = 0.008). Patients treated with pre-
gabalin had a clinically and statistically significant
effect after 4 weeks (ATE = −1.8; p = 0.016) and
showed a 61.7% reduction in pain from baseline to
week 8 (ATE = −3.53; p < 0.001) compared with the
control group. All participants treated with analgesia
experienced worsening of pain following discontinu-
ation of treatment during the washout period (acet-
aminophen: ATE = −0.76, p = 0.004; morphine or
buprenorphine: ATE = −0.223, p = 0.075 pregabalin:
ATE = −1.438, p = 0.075) (Fig. 5).
As previously reported (Husebo et al., 2011), no
significant differences were seen in ADL between
intervention and control groups at week 8 (p = 0.443).
However, a sub-analysis of the acetaminophen group
demonstrated improved ADL from baseline in the
intervention group (ATE = +1.00; p = 0.022) at week 8
compared with the control group (Fig. 6). Entering NH
unit as a nestling level did not alter our findings.
3.4 Adverse events
Adverse events related to pain treatment interventions
were registered for six patients (nausea n = 1, rash
from patch n = 1, reduced appetite n = 2, somnolence/
drowsiness n = 2). Most patients had acetaminophen
(n = 120), but few left the study due to side effects
(n = 2). Twice as many left from the opioid group
(n = 4), although this group counted only 33% com-
Assessed for eligibility (n = 420)
Excluded  (n = 93)
 Not meeting inclusion criteria (n = 47)
 Declined to participate (n = 4)
 No pain intensity score (n = 25)
MOBID-2 pain scale total score (n = 152)
Lost to follow-up  (n = 4)
 Died (n = 2)
 Moved (n = 2) 
MOBID-2 pain scale total score (n = 156)
Lost to follow-up  (n = 3)
 Died (n = 3) 
Allocated to care as usual (n = 163) 
MOBID-2 pain scale total score (n = 143)
Lost to follow-up  (n = 1)




Allocated to stepwise protocol for treatment
of pain (n = 164)  
Allocation
Randomized (n = 327)
Enrolment
MOBID-2 pain scale total score (n = 144)
Lost to follow-up  (n = 19)
 Withdrew consent (n = 3)
 Died (n = 5)
 Acute psychiatric illness (n = 3)
 Drowsiness (n = 2)
 Nausea (n = 1)
 Moved (n = 1)
 Skin allergic reaction (n = 1)
 Reduced condition (n = 1)
 Administration (n = 2)  
 
MOBID-2 pain scale total score (159)
Lost to follow-up  (n = 5)
 Died (n = 3)
Reduced condition (n = 1) 
Week 2
MOBID-2 pain scale total score (n = 137)
Lost to follow-up  (n =  6)
 Died (n = 3)
 Administration (n = 3)
Week 8
Week 4
Figure 1 Flow chart showing patients flow
through the 12-week study period including
control and intervention groups.
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pared with the acetaminophen group. Pregabalin was
given to 12 patients and 2 left the study. Fourteen
deaths occurred during the 8-week study, of which six
were participants in the intervention group.
4. Discussion
Pain is a clinically significant issue in dementia and is
known to be related to the development of challeng-
ing symptoms such as BPSD and to have a significant
impact on the quality of life and well-being. This
article reports the first study to specifically measure
the effect of pain treatment on the intensity of pain
in people with dementia living in NH. This secondary
analysis has shown that a stepwise approach to treat-
ing pain, which is tailored to the individual and
adapted according to the patients’ ongoing pain
medication, significantly improved overall pain
intensity in residents with moderate and severe
dementia as measured by the MOBID-2 Pain Scale.
Pain intensity was reduced by 45% in the interven-
tion group after 8 weeks of treatment. All treatments
resulted in benefit at the 8-week time point, with
pregabalin also conferring effective pain relief by
week 4, and acetaminophen providing benefit after 2
weeks. Importantly, all participants receiving analge-
sia experienced a significant worsening of pain when
treatment was discontinued at the end of the trial. In
addition to the impact on pain intensity, the study
also found a significant improvement in physical
function in participants receiving acetaminophen at 8
weeks. Pain is known to influence mobility and
ability to perform daily tasks, and this is an impor-
tant outcome. Since individuals receiving acetamino-
phen within step 1 of the SPTP for the full 8 weeks
were predominantly experiencing mild or moderate
pain, this finding indicates the additional value of
analgesia for these individuals. Taken together, these
findings clearly indicate the value of prompt and
ongoing analgesic treatment in people with dementia
where it is clinically appropriate.
Clinical guidelines for older adults have been pub-
lished by the AGS panel from 1998, with regular
updates in 2002 and 2009 (AGS Panel on Persistent
Pain in Older Persons, 2009). The latest version also
includes recommendations for accurate pain assess-
ment in patients with dementia. However, guidelines
for treatment of pain in patients with dementia are still
urgently needed. We applied the recommendations
from the AGS panel guidelines and focused upon titra-
tion and combination of two or more drugs with
complementary mechanisms to attain improved pain
reduction with less hepatic and kidney toxicity and
adverse effects. Following the recommendations for
clinicians, we used a maximum safe dose (<4 g/24 h)
of acetaminophen for our patients (AGS Panel on
Persistent Pain in Older Persons, 2009).
To our knowledge, this is also the first RCT to evalu-
ate the anti-epileptic pregabalin to specifically treat
neuropathic pain in patients with dementia. Treat-
ment followed recommendations by the AGS panel,
starting on low doses (25 mg/day), increasing to
75 mg/day where necessary. Pregabalin selectively
binds to voltage-gated calcium channels in the brain
and spinal cord and has been shown to decrease the
release of excitatory neurotransmitter and reduce
calcium channel function (Dooley et al., 2000;
Fehrenbacker et al., 2003; Micheva et al., 2006). Pre-
gabalin has shown initial benefit in an RCT of painful
diabetic neuropathy (Rosenstock et al., 2004). Despite
Table 1 Demographic and clinical characteristics of the study popula-







n = 164 p
Agea 86.4 (6.7) 85.2 (7.0) 0.102
Women (%)b 131 (74.0) 131 (74.9) 0.856
MMSEc,d 8.9 (6.6) 7.6 (6.6) 0.065
Barthel ADL indexc,e 8.7 5.5) 7.8 (5.6) 0.148
MOBID-2 Pain Scalec,f 3.7 (2.5) 3.8 (2.7) 0.988
MOBID-2 Pain Scale ≥ 1c 4.2 (2.2) 4.5 (2.4) 0.273
MOBID-2 Pain Scale ≥ 2c 4.5 (2.1) 4.9 (2.2) 0.213
MOBID-2 Pain Scale ≥ 3c 5.3 (1.8) 5.4 (2.0) 0.830
No pain diagnoses in total (%)c 29.4 29.4 0.823
1 pain diagnoses (%) 30.8 30.3
2 pain diagnoses (%) 24.4 22.6
≥3 pain diagnoses (%) 16.0 18.1
Old fracture (%)b 27.6 27.1 0.801
Arthritis (%)b 22.4 20.0 0.600
Osteoporosis (%)b 20.5 23.9 0.477
Heart (%)b 17.9 15.5 0.561
Cancer (%)b 16.7 20.0 0.448
Neuropathy (%)b 1.9 4.5 0.196
Wound gangrene (%)b 1.3 3.9 0.150
Muscle spasm (%)b 1.3 2.6 0.406
MMSE, Mini-Mental State Examination (scores from 0 to 30); ADL, activi-
ties of daily living (scores 0–20); MOBID-2, Mobilisation-Observation-
Behaviour-Intensity-Dementia-2 Pain Scale.
at-Test for continuous variable, normally distributed.
bChi-square test for dichotomous categorical variables.
cMann–Whitney U for unequal distributed continuous variable given in
medians (SE). Variables reported as mean (SD) and median (%) if not indi-
cated otherwise.
dLower scores indicate more cognitive impairment.
eHigher scores indicate better function.
fHigher scores indicate more pain (scores ≥ 3 accepted as clinically
relevant).
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only 12 participants receiving pregabalin, the data
indicate significant benefit. This finding is of particular
importance due to the frequency of central neuro-
pathic pain in people with dementia associated with
white matter lesions in people who have experienced
a stroke (Scherder et al., 2003; Scherder and Plooij,
2012). Studies also indicate the presence of neuro-
pathic pain in people with vascular dementia, mixed
dementia, Alzheimer’s disease and frontotemporal
dementia as a result of specific neuropathology
(Scherder et al., 2003; Rosenstock et al., 2004; Husebo
et al., 2008; Scherder and Plooij, 2012). Furthermore,
diabetes is particularly common among people with
dementia and is associated with considerable neuro-
pathic pain (Wild et al., 2004; Zilliox and Russell,
2011). Pregabalin therefore warrants further investi-
gation as an analgesic treatment option for this group.
Our dataset has revealed valuable data regarding the
specific tolerability of different pharmacological treat-
ments for pain in this patient group. The largest pro-
portion of participants in the trial who received
treatment was prescribed with acetaminophen. This
Table 2 Efficacy of treating pain on different locations of pain with the sum scores of musculoskeletal pain (MOBID-2 part 1) and pain from internal organs
head and skin (MOBID-2 part 2) between control group and treatment group at baseline and in week 8 (n = 327).
Pain location








(SE) Difference dfa ta pa
Hands 0.8 (0.2) 1.0 (0.1) 0.161 1.1 (0.2) 0.8 (0.2) −0.243 1183 −2.457 0.014
Arms 1.7 (0.2) 1.8 (0.2) 0.119 1.8 (0.2) 1.2 (0.2) −0.677 1180 −2.868 0.004
Legs 2.6 (0.2) 2.2 (0.2) −0.342 2.0 (0.2) 1.6 (0.2) −0.375 1174 −0.177 0.859
Turn over 1.9 (0.2) 2.0 (0.2) 0.026 2.0 (0.2) 1.3 (0.2) −0.739 1156 −2.665 0.008
Sit 1.6 (0.2) 2.0 (0.2) 0.398 2.1 (0.2) 1.2 (0.2) −0.826 1154 −4.498 <0.001
Part 1 total score 8.7 (0.8) 8.9 (0.7) 0.393 9.0 (0.8) 5.8 (0.8) −3.233 1132 −3.567 <0.001
Head, mouth, neck 1.0 (0.1) 0.9 (0.1) −0.091 1.4 (0.2) 0.8 (0.1) −0.627 1184 −2.548 0.011
Heart, lung, chest 0.8 (0.2) 0.8 (0.1) 0.049 0.8 (0.1) 0.4 (0.1) −0.426 1182 −2.675 0.008
Abdomen 0.9 (0.1) 0.7 (0.1) −0.143 1.0 (0.2) 0.4 (0.1) −0.546 1182 −1.823 0.069
Pelvis, genital organs 1.6 (0.2) 1.6 (0.2) −0.023 1.8 (0.2) 0.8 (0.2) −0.944 1182 −3.276 0.001
Skin 1.7 (0.2) 1.4 (0.2) −0.208 1.5 (0.2) 1.0 (0.2) −0.570 1184 −1.458 0.145
Part 2 total score 5.9 (0.5) 5.4 (0.4) −0.416 6.5 (0.5) 3.4 (0.4) −3.113 1177 −3.766 <0.001
Overall pain intensity 3.7 (0.2) 3.4 (0.2) −0.297 3.8 (0.2) 2.1 (0.2) −1.655 1123 −5.277 <0.001
df, degree of freedom; SE, standard error.
Part 1 = musculoskeletal pain.
Part 2 = pain related to internal organs head and skin.
aRandom-intercept model in a two-way repeated-measure configuration.
Figure 2 MOBID-2 Pain Scale total score withmean and standard error of
the mean by control and treatment group over study period in total study
sample.
Figure 3 Mean and standard error of the mean in musculoskeletal pain
(MOBID-2 Pain Scale part 1) scores by control and intervention groups
over study period.
Pain treatment in dementia R.K. Sandvik et al.
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
1496 Eur J Pain 18 (2014) 1490–1500
treatment was extremely well tolerated. Only 2 of 120
patients left the study, both because patient’s relatives
withdrew consent. Acetaminophen is therefore both
effective and very well tolerated by people with
dementia, confirming the suitability of this agent as a
first-line analgesic. Forty participants received an
opioid analgesic (extended release morphine or
buprenorphine transdermal patch), of whom four
withdrew due to possible side effects (femur fracture,
drowsiness and nausea, local reaction to the transder-
mal patch, appetite and eating disturbances). This
outcome reflects the literature, which indicates that
the opioid drug class is generally well tolerated with
the most common adverse drug reactions being
arrhythmia (12.1%), pruritus (10.5%), nausea (9.2%)
and dizziness (4.6%) (Hamunen et al., 2008; Huang
and Mallet, 2013), in addition to an increased risk of
falls and hip fractures (Deandrea et al., 2010). While
buprenorphine appears to be safe in people with renal
impairment, it should be noted that due to the meta-
bolic pathway of this agent, careful monitoring is
required in people with hepatic impairment, and this
is an important consideration when prescribing to
people with dementia. The only previous RCT of an
opioid for pain in dementia reported a high 47%
dropout rate (Manfredi et al., 2003). Our study has
demonstrated efficacy and improved tolerability with
buprenorphine administered through transdermal
patches, which are already in use to treat chronic
nociceptive, neuropathic and cancer-related pain
(Pergolizzi et al., 2010). Following recommendations
by the AGS panel to keep stable blood levels, 12
patients received the buprenorphine patch only, as
they already were on a strong morphine option and
had swallowing difficulties.
The late-onset effect of buprenorphine transdermal
patch after 8 weeks was an unexpected finding. Cog-
nitive function and ADL function were stable over the
period, suggesting that reduced pain was a treatment
effect and not related to sedation. The lower tolerabil-
Figure 4 Mean and standard error of the mean in pain related to internal
organs, head and skin (MOBID-2 Pain Scale part 2) by control and inter-
vention groups over study period.
Figure 5 MOBID-2 Pain Scale total score withmean and standard error of
the mean, ordered by different analgesics (acetaminophen, extended
release morphine and buprenorphine transdermal patch and pregabalin)
and control group over study period.
Figure 6 Activity of daily living total score with mean and standard error
of the mean, in order to different analgesics (acetaminophen, extended
release morphine and buprenorphine transdermal patch and pregabalin)
and control groups over study period.
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ity of opioids in people in dementia indicates the need
for an intermediate analgesic as an alternative to esca-
lation to opioids where acetaminophen is not suffi-
cient. There are both benefits and harms associated
with the use of non-steroidal anti-inflammatory drugs
(Huang et al., 1999; Bannwarth, 2008), and a further
evaluation of this analgesic group could be of value in
informing the management of pain in people with
dementia in the future.
Withdrawal among participants receiving pregaba-
lin was relatively high in this study, with 2 of 12
participants withdrawing due to somnolence, nausea
and drowsiness. This occurred despite the lower
dosage used in the study (25 mg) compared with the
recommended daily dose of 150 mg used in younger
individuals where the safety profile is very good. This
provides the first safety data for pregabalin in this
patient group. However, our results have to be con-
trolled by a clinical trial with appropriate sample
size.
To date, the prevalence of pain in people with
dementia in NH has not been fully established. While
it was not the primary purpose of this study, baseline
data indicate that almost 60% of these individuals
were experiencing significant pain, with a pain score
of at least 3. Furthermore, almost 70% had one or
more diagnoses of pain, indicating an extensive preva-
lence of pain. The pattern of prescribing within the
SPTP also indicates that many individuals were receiv-
ing suboptimal analgesia prior to the study commenc-
ing, most likely due to undiagnosed mild or moderate
pain. These secondary findings provide further weight
to the need for more effective identification of pain in
dementia through an accurate and easily implement-
able assessment and monitoring tool. The MOBID-2
Pain Scale utilized in this study has shown excellent
reliability and sensitivity to date, and this study further
confirms its utility in research. It will now be essential
to further establish its use in clinical practice in order
to provide health-care professionals with adequate
knowledge, as well as an effective pain assessment
(Pieper et al., 2013).
This is the largest study to have investigated the
effect of pain treatment on pain intensity in people
with dementia living in NH. It has provided robust,
well-powered and clinically meaningful data that
demonstrate the efficacy of a stepped pharmacological
treatment approach in this patient group. A possible
limitation in this study may be the heterogeneous
nature of the dementia cohort as no definition was
made of the sub-types of dementia within the partici-
pants. However, due to the frequent absence of a
differential diagnosis in people with dementia in NH, it
is more meaningful to consider treatment effects in
this group since it is representative of the current
clinical situation and will provide information that can
be directly translated to guidance for practice. The data
provide robust data for the overall cohort. Efficacy
data for the individual pharmacological agents are
necessarily derived from smaller groups of participants
due to the stepped nature of the intervention. It would
therefore be a valuable next step to evaluate each of
the agents in larger cohorts to confirm the efficacy
demonstrated in this study. Further evaluation of
alternative treatment options such as anticonvulsants,
antidepressants and novel analgesics is also urgently
needed in order to establish the most effective step-
wise treatment regimen for this patient group.
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a b s t r a c t
Objectives: To investigate whether it is possible to determine signs of imminent dying and change in pain
and symptom intensity during pharmacological treatment in nursing home patients, from day perceived
as dying and to day of death.
Design: Prospective, longitudinal trajectory trial.
Setting: Forty-seven nursing homes within 35 municipalities of Norway.
Participants: A total of 691 nursing home patients were followed during the first year after admission and
152 were assessed carefully in their last days of life.
Measurements: Time between admission and day of death, and symptom severity by Edmonton symptom
assessment system (ESAS), pain (mobilization-observation-behavior-intensity-dementia-2), level of de-
mentia (clinical dementia rating scale), physical function (Karnofsky performance scale), and activities of
daily living (physical self-maintenance scale).
Results: Twenty-five percent died during the first year after admission. Increased fatigue (logistic
regression, odds ratio [OR] 1.8, P ¼ .009) and poor appetite (OR 1.2, P ¼ .005) were significantly associated
with being able to identify the day a person was imminently dying, which was possible in 61% of the
dying (n ¼ 82). On that day, the administration of opioids, midazolam, and anticholinergics increased
significantly (P < .001), and was associated with amelioration of symptoms, such as pain (mixed-models
linear regression, 60% vs 46%, P < .001), anxiety (44% vs 31%, P < .001), and depression (33% vs 15%,
P < .001). However, most symptoms were still prevalent at day of death, and moderate to severe dyspnea
and death rattle increased from 44% to 53% (P ¼ .040) and 8% to 19% (P < .001), respectively. Respiratory
symptoms were not associated with opioids or anticholinergics.
Conclusion: Pharmacological treatment ameliorated distressing symptoms in dying nursing home pa-
tients; however, most symptoms, including pain and dyspnea, were still common at day of death. Results
emphasize critical needs for better implementation of guidelines and staff education.
Trial registration: ClinicalTrials.gov NCT01920100.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The rapidly aging population, combined with substantial urban
changes in the society, makes the role of institutional care increasingly
important for the dying old. Every year, approximately 20% of all dying
UK citizens1 and almost 50% of the dying Norwegian population, die in
a nursing home.2
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More than 80% of all nursing home patients have dementia, a
chronic, usually progressive and incurable disease, with increased
risk of neuropsychiatric symptoms and mortality.3,4 To enhance
advance care planning and end-of-life care in nursing homes, mid-
and short-term prognostication5 and pain and symptom manage-
ment are key responsibilities for the clinician.6,7 According to the
newest National Institute for Health and Care Excellence (NICE)
guidelines, Care of dying adults in the last days of life, the recognition
and weighing up of factors that may indicate that someone is
imminently dying are complex and underestimated.8 Challenges are
even more urgent in nursing home patients and people with de-
mentia.9 Mitchell et al10 demonstrated that pneumonia, repeated
episodes of fever, and eating problems increased the 6-month
mortality risk in people with dementia. In the last 3 months of
life, dyspnea, pain, and pressure ulcers were identified to be the
most common and distressing symptoms in these individuals.
However, many nursing home patients die unexpectedly and sud-
denly because signs and symptoms for prognostication of the
imminent death are not yet established, leading to increased
suffering of the individual.11 A Dutch observational study reported
that identifying a patient as terminally ill was possible only when
the person died within the next 3 days.12 Patients in this study were
recognized as imminent dying by the lack of fluid and nutrition
intake, general weakness, dyspnea, and somnolence. Another
nursing home study found significant decrease of pain and dis-
tressing symptoms during the last 2 days of life, by retrospective
observation.13 Contrary to these findings, pain, agitation, and dys-
pnea were found in 6% to 71% of affected patients, in the last week
and days before death.14
Better predictability and treatment of these symptoms may
contribute to the overall end-of-life care in nursing homes, and most
recent recommendations emphasized the importance of prospective
studies in elderly patients and people with dementia.15 Few studies
have, however, assessed prospectively the change of pain and symp-
tom intensity alongside pharmacological treatment, from the day
when the patient was imminently dying and to the day of death.
We identified, prospectively, typical signs and symptoms prevalent
on the day when the patient was imminently dying and the day of
Table 1
Measurement Tools Used in the Study
What Does the Tool Measure? Tool Characteristics and Psychometric Properties Time Point for Measurement
ESAS Pain and distressing symptoms (fatigue, drowsiness,
nausea, appetite disturbances, dyspnea, depression,
anxiety, and well-being)
Edmonton symptom assessment system (ESAS)
evaluates subitem intensity on an 11-point Likert
scale (range 0e10). Intensity is grouped as none to
mild (0e2), mild to moderate (3e6), and moderate to
severe (7e10).37 ESAS has shown good psychometric
properties, and has been used in dying people with
dementia.15e17
Baseline
ESAS Pain and distressing symptoms (fatigue, drowsiness,
nausea, appetite disturbances, dyspnea, depression,
anxiety, sleep, vomiting, delirium, agitation, death
rattle, and constipation)
ESAS evaluates subitem intensity on an 11-point Likert
scale (range 0e10). Intensity is grouped as none to
mild (0e2), mild to moderate (3e6), and moderate to
severe (7e10).37 ESAS has shown good psychometric
properties, and has been used in dying people with
dementia.15e17
Day perceived as dying,
day of death
CDR Cognitive staging tool Clinical dementia rating (CDR) consists of 5 steps (0e3)
distributed as follows: no dementia (0 and 0.5), mild
dementia (1), moderate dementia (2), severe
dementia (3). CDR is a reliable, valid, and feasible tool,
validated in the Norwegian language.27
Baseline
KPS Functional performance status Karnofsky performance status scale (KPS) is an 11-step
rating scale from normal function (100), to dead (0).
KPS demonstrates good psychometric properties in
patients with cancer and in elderly people.21
Baseline,
day perceived as dying
MMSE Cognitive staging tool with 8 domains (orientation to
time and place, short-term recall, attention, and
calculation, long-term recall, language, repetition, and
complex commands)
Mini-mental state examination (MMSE) is a 30-point
questionnaire (0e30); severe impairment (0e11),
moderate impairment (12e17), mild impairment
(18e23), and no impairment (24e30). MMSE is
widely used and demonstrates good validity and
reliability.23e26
Baseline
MOBID-2 Pain intensity and pain location from musculoskeletal
pain (Part 1), and pain from internal organs, head, and
skin (Part 2)
Mobilization-observation-behavior-intensity-
dementia-2 Pain Scale (MOBID-2) assesses pain
intensity and pain location based on patient’s pain
behavior during standardized, guided movements.
The 10 items are scored on a 0e10 numerical rating
scale (0 ¼ no pain, 10 ¼ severe pain). Based on all
observations, the patient’s overall pain intensity is
rated again on a 0e10 scale. MOBID-2 has excellent
reliability, validity, and good responsiveness.18
Baseline,
day perceived as dying
day of death
PSMS Activities of daily living are assessed by 6 domains
(toileting, eating, dressing, grooming, transfer, and
bathing)
Lawton and Brody physical self-maintenance scale
(PSMS) has 6 domains, each scored on a scale from
1e5 (range 6e30). Increasing numbers means
increasing dependence in daily functioning. Good
reliability and validity, and sensitive to change in
severe dementia.19,20
Baseline
RAI-PC Distressing symptoms, care and treatment provided Residents Assessment Instrument for Palliative Care
(RAI-PC) consists of 8 domains (symptoms,
communication, mood, functional status, preferences,
social relations, spirituality, and treatments), of which
we included items for mouth care, bedsores, and
nutrition.22
Baseline,
day perceived as dying,
day of death
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death. Further, we investigated whether opioids, anxiolytics, and
anticholinergics were associated with change of pain and symptom
intensity between these 2 time points.
Methods
This was a prospective, multicenter longitudinal trajectory study
including 47 nursing homes from 35 municipalities, in 4 counties of
Norway. Between January 2012 and June 2014, eligible participants,
aged 65 years and older or younger people with an early diagnosis of
dementia, were included. They were all admitted to long-term care
units and had an expected survival of 6 weeks or more as judged by
the multidisciplinary team (responsible nursing home physician, the
responsible nurse, and the primary caregiver). Data were collected for
each patient individually, at admission to the nursing home (baseline),
at the day the personwas perceived as dying (imminent dying), and at
the day of death. In our analyses, we included only patients followed
for at least 1 year until January 1, 2015, or until death.
Registered nurses and licensed practical nurses (usually the pri-
mary caregiver) with close knowledge of the patient performed all
assessments under supervision by experienced research nurses.When
a patient was not able to give valid self-report due to dementia or
unconsciousness, the primary caregiver performed as a proxy-rater.
The assessors participated in a 2-day standardized training program
(12 hours) and received specific training in use of the instruments,
before the data collection. End-of-life carewas performed according to
standard procedures at each individual nursing home. When a patient
showed deteriorating health conditions, the multidisciplinary team
evaluated whether the individual was imminently dying by clinical
signs due to their own clinical experience. On this day and at the day of
death, data were compiled in a telephone interview between the
patient’s primary caregiver and the research nurse, including stan-
dardized measurement scales (Table 1).
Pain and distressing symptoms were assessed at baseline (T0), the
day a patient was imminently dying (T1), and the day of death (T2),
using the Edmonton symptom assessment system (ESAS) with symp-
toms of fatigue, drowsiness, nausea, poor appetite, dyspnea, depres-
sion, anxiety, and well-being.16 Six additional symptoms (sleep
disturbances, vomiting, delirium, agitation, death rattle, and con-
stipation) were also assessed at T1 and T2 (Table 1). Moderate and
severe symptoms on the ESAS scores (score 3) were regarded as
clinically significant.17 The scale has been used and validated for proxy-
rating,18 but has not yet been used in dying patients with dementia. We
Fig. 1. Study flow chart for 691 patients individually admitted to 47 Norwegian nursing homes (NH) from January 2012 to June 2014.
Table 2
Baseline Clinical Characteristics for Patients Admitted Individually to a Nursing












Age, y, mean (SD) 86.3 (7.5) 86.4 (6.9) 86.3 (7.7) .944
Female, n (%) 388 (63.9) 90 (59.2) 298 (65.5) .162
KPS (0e100), mean (SD) 54.3 (28.8) 53.9 (53.9) 54.4 (14.0) .882
MMSE (0e30), mean (SD) 16.2 (6.5) 15.7 (7.0) 16.3 (6.4) .549
CDR (0, 0.5), n (%) 78 (13.3) 23 (16) 55 (12.4) .006
CDR (1), n (%) 142 (24.1) 33 (22.9) 109 (24.5)
CDR (2), n (%) 247 (41.9) 47(32.6) 200 (44.9)
CDR (3), n (%) 122 (20.7) 41 (28.5) 81 (18.2)
PSMS (6e30), mean (SD) 15.4 (0.2) 17.3 (4.8) 14.8 (4.3) <.001
MOBID-2 (0e10), mean (SD) 2.1 (0.1) 2.3 (2.3) 2.0 (2.1) .199
ESAS symptoms, mean (SD)
Pain, mean (SD) 2.6 (2.6) 3.1 (2.6) 2.5 (2.5) .044
Fatigue, mean (SD) 2.9 (2.7) 3.6 (3.1) 2.7 (2.6) .001
Drowsiness, mean (SD) 2.7 (2.7) 3.6 (2.9) 2.5 (2.5) .001
Nausea, mean (SD) 0.6 (1.6) 0.8 (1.9) 0.6 (1.5) .211
Poor appetite, mean (SD) 1.4 (2.5) 2.0 (3.0) 1.2 (2.3) .003
Dyspnea, mean (SD) 1.3 (2.2) 2.0 (2.8) 1.0 (2.0) <.001
Depression, mean (SD) 2.4 (2.6) 2.4 (1.9) 2.3 (2.6) .771
Anxiety, mean (SD) 2.2 (2.8) 2.6 (3.2) 2.1 (2.7) .088
Well-being, mean (SD) 3.0 (2.5) 3.5 (2.7) 2.9 (2.4) .019
RAI-PC items, n (%)
Problems chewing 26 (7.2) 11 (12.1) 15 (5.6) .037
Problems swallowing 28 (7.8) 12 (13.2) 16 (5.9) .025
Mouth pain 11 (3.1) 7 (7.7) 4 (1.5) .003
Nutritional problems 57 (15.8) 19 (20.9) 38 (14.1) .127
Nutritional substitute 55 (15.3) 22 (24.2) 33 (12.3) .006
Bedsore, stage 1 41 (12.4) 17 (20.7) 24 (9.6) .008
Bedsore, stage 2 52 (15.9) 24 (29.6) 28 (11.4) <.001
Bedsore, stage 3 14 (4.4) 7 (9.3) 7 (2.9) .017
Bedsore, stage 4 5 (1.6) 1 (1.3) 4 (1.7) .846
CDR, higher score indicates higher cognitive impairment; ESAS, higher scores
indicate more severe symptoms; KPS, lower scores indicate more dependence;
MMSE, lower scores indicate more cognitive impairment; PSMS, increasing
numbers indicate higher dependency.
*P value from exact c2 test for dichotomous variables and otherwise t test
comparing those who died within 1 year with those who were alive after 1 year.
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also investigated pain (T0, T1, T2) (scores on mobilization-observation-
behavior-intensity-dementia-2 [MOBID-2]),19 activities of daily living
(physical self-maintenance scale [PSMS]),20,21 and physical function by
the Karnofsky performance scale (KPS).22 We further included the
items for nutrition, bedsores, and mouth care assessed by the resident
assessment instrument for palliative care (RAI-PC).23 Cognition and
level of dementia were assessed by mini-mental state examination
(MMSE)24e27 and clinical dementia rating scale (CDR) at T0.28 Admin-
istered pharmacological treatment and the causes of death were
collected from the patients’ medical records.
At nursing home admission, verbal and written informed consent
was obtained in direct conversations with all cognitively intact pa-
tients with sufficient ability to consent. In patients lacking the ability
to consent, verbal and written informed and presumed consent was
obtained in direct conversationwith the patient (if possible) and his or
her legal guardian, usually a family member, after explaining the aims
and protocol of the study. The study was approved by the Regional
Committee for Medical and Health Research Ethics 2011/1738, and
registered at clinicaltrials.gov NCT01920100.
Continuous variables were described by means and SDs, and cat-
egorical variables by percentages of sample size and c2 square test.
The change within individuals in continuous variables was analyzed
with the paired t test. To examine differences between groups and
time points, we also built regression models for repeated measure-
ments with random effects for intercepts: linear mixed model for
continuous and multilevel logistic regression for dichotomous
outcome variables. We regarded P < .050 as significant and P< .001 as
highly significant. Statistical analyses were conducted with IBM SPSS
Statistics for Windows version 21.0 (IBM Corp, Armonk, NY), and
STATA/IC 13.1 (Stata Corp, College Station, TX).
Results
In all, 691 patients from 47 Norwegian nursing homes were
included for the baseline assessment (T0). Forty-seven patients were
excluded from further follow-up testing because they moved home or
to other institutions or declined to participate (Figure 1). To avoid
noninformative censoring, we also excluded 37 patients with nursing
home stay less than 1 year. This left 607 patients for the follow-up
analyses, of whom 369 (63%) had moderate to severe dementia ac-
cording to the CDR scale (Table 2). A total of 152 patients (25%) died
during the first year; of those, 18 were excluded from our analyses
because of missing data (Figure 1). The remaining 134 patients were
all assessed on their day of death (T2). For 82 patients (61%), the
multidisciplinary team identified the day of imminent dying (T1),
whereas 52 patients were not recognized as dying, in advance. Thus,
our analyses comprised 82 patients at T1 and 134 at T2. The median
number of days between T1 and T2 was 3 (range 0e73); 63% died
between day 0 and 2, 21% died between days 3 and 7, and 15% died on
day 8 or more.
Predictors for 1-Year Mortality
Patients (n ¼ 152, 25%) who died during the first year had more
dyspnea (P < .001), drowsiness (P ¼ .001), fatigue (P ¼ .001), pain
(P ¼ .044), and dependency in daily activities (P < .001) at admission
(T0), and experienced less well-being (P ¼ .019) and appetite
(P ¼ .003), compared with those who were still alive after 1 year
(n ¼ 455) (Table 2). These patients had also more chewing and
swallowing problems (P ¼ .037, P ¼ .025, respectively), pain in the
mouth (P ¼ .003), nutritional substitution (P ¼ .006), and bedsores
stage 1, 2, and 3 (P ¼ .008, P < .001, and P ¼ .017, respectively). Di-
agnoses of death suggested that 21% died of pneumonia, followed by
heart failure (18%), dementia (15%), stroke (15%), and cancer (7%) or
kidney failure (7%). In 17% of the patients, diagnoses of death were
missing for administrative reasons.
Signs and Symptoms of Imminent Dying (T1)
Shown in Table 3, fatigue (99%), drowsiness (98%), and reduced
appetite (95%) were the most frequently observed ESAS symptoms
with moderate to severe intensity at T1. Moderate to severe pain
assessed with ESASwas found in 60% of the patients, highly correlated
Table 3
Proportion of Patients (%) Categorized According to Severity of ESAS Symptoms in
Nursing Home Patients at Day of Imminently Dying and Day of Death
Symptoms Day of Imminently




% 95% CI % 95% CI
Pain, 0e10 <.001
0e2 39.7 (29.3e51.2) 54.2 (45.1e63.0)
3e6 34.6 (24.7e46.0) 32.5 (24.6e41.5)
7e10 25.6 (17.0e36.7) 13.3 (8.3e20.8)
Fatigue, 0e10 .001
0e2 1.3 (0.0e0.9) 10.6 (6.2e17.5)
3e6 17.9 (10.8e28.3) 10.5 (6.2e17.5)
7e10 80.8 (70.3e88.2) 78.9 (70.6e85.3)
Drowsiness, 0e10 <.001
0e2 2.5 (0.6e1.0) 12.2 (7.4e19.3)
3e6 19.2 (11.8e29.7) 11.4 (6.8e18.4)
7e10 78.2 (67.4e86.1) 76.4 (68.0e83.2)
Sleep quality, 0e10 <.001
0e2 50 (38.7e61.3) 61.2 (51.4e70.3)
3e6 31.6 (22.0e43.1) 19.1 (12.9e27.5)
7e10 18.4 (11.1e29.0) 19.1 (12.9e27.5)
Nausea, 0e10 <.001
0e2 75.6 (64.7,84.0) 87.7 (80.5e92.3)
3e6 19.2 (11.8e29.7) 6.6 (3.2e12.7)
7e10 5.1 (1.9e13.1) 5.7 (2.7e11.7)
Vomiting, 0e10 <.001
0e2 84.6 (74.6e91.2) 90.2 (83.5e94.4)
3e6 10.2 (5.1e19.4) 5.7 (2.7e11.6)
7e10 5.1 (1.9e13.1) 4.1 (1.7e9.5)
Poor appetite, 0e10 <.001
0e2 5.2 (1.9e13.3) 21.7 (15.4e30.3)
3e6 6.5 (2.7e14.9) 9.6 (5.3e16.6)
7e10 88.3 (78.8e93.9) 68.7 (59.5e76.6)
Dyspnea, 0e10 .040
0e2 56.6 (45.0e67.5) 47.1 (38.3e56.1)
3e6 22.4 (14.2e33.4) 24.0 (17.1e32.5)
7e10 21.1 (13.2e31.9) 29.0 (21.5e38.0)
Depression, 0e10 <.001
0e2 66.7 (55.0e76.6) 84.9 (77.1e90.3)
3e6 16.0 (9.2e26.4) 8.4 (4.5e15.0)
7e10 17.3 (10.2e27.9) 6.7 (3.3e13.0)
Anxiety, 0e10 <.001
0e2 55.8 (44.4e66.7) 69.1 (60.3e76.7)
3e6 24.7 (16.2e35.8) 15.4 (10.0e23.1)
7e10 19.5 (12.0e30.1) 15.4 (10.0e23.1)
Delirium, 0e10 <.001
0e2 84.0 (73.6e90.8) 91.1 (84.4e95.0)
3e6 8.0 (3.6e16.9) 2.4 (3.3e12.6)
7e10 8.0 (3.6e17.0) 0.7 (0.1e0.7)
Agitation, 0e10 <.001
0e2 90.8 (81.6e95.6) 96.7 (91.5e98.8)
3e6 6.6 (2.7e15.1) 2.4 (0.1e0.7)
7e10 2.6 (0.6e10.2) 0.8 (0.1e5.7)
Death rattle, 0e10 <.001
0e2 92.3 (83.7e96.6) 81.5 (73.5e87.4)
3e6 5.1 (1.8e13.1) 10.4 (6.1e17.3)
7e10 2.6 (0.6e10.0) 8.1 (4.4e14.5)
Constipation, 0e10 <.001
0e2 75.6 (64.7e84.0) 91.8 (85.3e95.6)
3e6 20.5 (12.8e31.2) 7.3 (3.8e13.7)
7e10 3.5 (1.2e11.5) 0.8 (0.1e5.7)
*Mixed-models linear regression symptom as dependent variable and time as
independent variable
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with the total scores on the MOBID-2 Pain Scale (Spearman rho cor-
relation 0.618, P < .001). Moderate to severe degree of sleep distur-
bances (50%), anxiety (44%), dyspnea (44%), and depression (33%)
were also common at T1.
We entered the variable identified/not identified as imminently
dying into logistic regression analyses with all ESAS symptoms at day of
death. We found that increased fatigue (odds ratio [OR] 1.8, 95% con-
fidence interval [CI] 1.16e2.85, P¼ .009) and poor appetite (OR 1.2, 95%
CI 1.06e1.41, P ¼ .005) were significantly associated with being able to
identify the day a person was imminently dying; however, symptoms
of pain or dyspnea did not contribute to the recognition of imminent
dying, and the presence of deliriumwas associated with not being able
to identify a person as dying at T1 (OR 0.6, 95%CI 0.4e0.9, P ¼ .010).
Pain and Symptom Intensity at Day of Death (T2)
Moderate and severe degree of fatigue (89%), drowsiness (88%),
and reduced appetite (78%) were still most frequently observed at T2
(Table 3). We found a proportional amelioration in patients with pain
(60% vs 46%, P < .001), anxiety (44% vs 31%, P < .001), depression (33%
vs 15%, P < .001), nausea (24% vs 12%, P < .001), constipation (24% vs
8%, P < .001), and delirium (16% vs 3.1%, P < .001) from T1 to T2.
Dyspnea was frequently observed in the patients, and increased from
44% to 53% (P ¼ .040). The proportion of patients with death rattle
increased from 8% to 19% (P < .001) (Table 3). Between T1 and T2, the
prevalence of agitation and delirium together decreased from 28% to
19% (P < .001). Patients who in advance were identified as dying
(n¼ 82, 61%) showed significantly more fatigue (P< .001), drowsiness
(P ¼ .006), and loss of appetite (P < .001) compared with those who
died unexpectedly (n ¼ 52, 39%).
Pain and Symptom Management in the Last Days and Hours of Life
Paracetamol was the most frequently used drug (52%) on day of
imminent dying. The administration of strong opioids increased from
48% to 66% (P < .001) and weak opioids increased from 4% to 37%
(P < .001) between T1 and T2. The use of midazolam doubled from 9%
to 17% (P< .001), whereas anxiolytics, in general, were stable with 29%
at T1 and 30% at T2 (P ¼ .781). Anticholinergic drug prescription
increased from 6% to 19% (P < .001), and antiemetics decreased from
15% to 10% (P ¼ .008) (Table 4). The linear mixed-models regression
analyses investigated changes in ESAS symptom scores only in pa-
tients (n ¼ 75) who started pharmacological treatment between T1
and T2 (Table 5). The initiation of opioids was associated with reduced
pain intensity (P ¼ .041), nausea (P ¼ .035), death rattle (P ¼ .016), and
agitation (P¼ .002), but not dyspnea (P ¼ .350). The use of anxiolytics/
sedatives was associated with the reduction of nausea (P ¼ .031),
agitation (P ¼ .015), death rattle (P ¼ .011), and dyspnea (P ¼ .007).
Finally, anticholinergics were associated with reduced anxiety
(P ¼ .012) and agitation (P < .001) but not death rattle.
Discussion
This study found that 1 in 4 patients died during the first year after
nursing home admission, most often with diagnoses of pneumonia,
heart failure, and dementia. The day of imminent dying was identified
in 61% by fatigue and poor appetite. In the last days of life, the
administration of opioids, midazolam, and anticholinergics increased
significantly and was associated with the amelioration of symptoms
such as pain, anxiety, and depression.
This was, to our knowledge, the first study that prospectively
assessed the change of pain and symptom intensity between the day of
imminent dying (T1) and the day of death (T2). Alarming findings un-
covered the high number of patients who still experienced dyspnea
(53%), pain (46%), sleep problems (40%), and anxiety (31%) at T2.
Moreover, the prevalence of death rattle increased from 8% to 19%.
Compared with other studies,11,14 agitation and delirium were less
frequently observed at the end of life. It is uncertain, however, whether
amelioration of agitated symptomswas related only to the treatmentof
pain or increased physical weakness over time.11 A possible under-
detection of deliriummight limit our results, as we did not include any
specific tool assessing this disease by a valid delirium tool, such as the
Confusion Assessment Method.29 Although the administration of opi-
oids increased from 44% to 66% betweenT1 and T2 in our study, figures
were lower in a comparable study inwhich all patients (100%) received
morphine (in mean 30 mg per day).11 Nuanced interpretation of these
results is required because the use of morphine, as a “one-size-fits-all”
solution, doesnotnecessarilyguaranteegood treatment. Tovalidate the
efficacy, it is a prerequisite to assess pain and symptom intensity before
and after symptommanagement has been initiated.30
Table 5
Change in ESAS Symptom Severity Between the Day of Imminently Dying and the Day of Death
Treatment
Symptoms
Opioids, *n ¼ 58 Anxiolytics/sedatives, yn ¼ 27 Anticholinergic drugs, zn ¼ 24
b 95% CI P b 95% CI P b 95% CI P
Pain 1.04 (2.03 to 0.04) .041 1.00 (2.50 to 0.54) .206 1.45 (3.02 to 0.12) .071
Nausea 0.82 (1.59 to 0.58) .035 0.92 (1.76 to 0.08) .031 1.25 (2.53 to 0.41) .058
Death rattle 1.05 (0.20 to 1.91) .016 1.96 (0.45 to 3.47) .011 1.01 (0.05 to 2.08) .063
Dyspnea 0.60 (0.66 to 1 to 86) .350 2.54 (0.71 to 4.37) .007 0.15 (1.74 to 2.03) .878
Agitation 1.13 (1.85 to 0.41) .002 0.27 (2.29 to 0.25) .015 2.12 (3.23 to 0.90) .001
Anxiety 1.18 (2.41 to 0.04) .058 0.80 (2.90 to 1.29) .451 2.49 (4.44 to 0.55) .012
Only patients who newly started with the treatment were included in these analyses. Investigated with linear mixed-models regression analysis; ESAS subitems as dependent
variables.
*Codeine, tramadol, morphine, fentanyl, oxycodone, buprenorphine.
yBenzodiazepines (including midazolam).
zScopolamine, morphine-scopolamine, glycopyrronium bromide.
Table 4
Proportion of Patients (%) by Administered Analgesic Drugs at Day of Imminently
Dying and Day of Death
Drugs Day of Imminently




% 95% CI % 95% CI
Paracetamol 51.9 40.8e62.7 35.1 27.4e43.6 .445
Weak opioidsy 3.7 1.2e11.1 37.3 29.5e45.9 <.001
Strong opioidsz 48.1 37.3e59.2 65.7 57.1e73.3 <.001
Benzodiazepines 23.5 15.3e34.1 13.4 8.6e20.4 .841
Midazolam 8.6 4.1e17.3 17.2 11.6e24.6 <.001
Antiemetics 1.2 1.2e8.5 3.0 1.1e7.8 .174
Anticholinergicsx 6.2 2.5e14.2 18.6 12.9e26.3 <.001
Haloperidol 6.2 2.5e14.2 6.0 3.0e11.6 .255
*Mixed-models linear regression symptom as dependent variable and time as
independent variable not P value from exact c2 test.
yCodeine, tramadol.
zMorphine, fentanyl, oxycodone, buprenorphine.
xGlycopyrronium bromide, morphine-scopolamine, scopolamine.
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In the present and also other studies,11,13,14 the most prevalent
distressing symptomwas dyspnea (53%), complicated by its subjective
burden with multiple potential etiologies, such as pneumonia and
lung edema in connection to heart failure.14,31 Although the exact
mode of action of opioids in dyspnea management is unknown, pe-
ripheral and central mechanisms have earlier been postulated.32 Thus,
it was an unexpected finding that opioids were not associated with
reduction of the dyspnea intensity scores in our study. Although it is
widely held that glycopyrrolate and scopolamine subcutaneously are
useful treatments of death rattle in patients with cancer,33 it may be
difficult for nursing home staff to distinguish between death rattle and
sounds of accumulating secretion in connection with pneumonia or
heart failure with lung edema.34 Diagnostic challenges also may be
apparent for nausea in connection with newly started opioids in
peoplewho are no longer able to describe their suffering. Caregivers in
our study observed nausea in only a very few patients; other studies
did not mention this symptom.10,11,14
Although it is broadly believed that the identification of imminent
dying is a hallmark to initiate end-of-life care, the frequency and
severity of typical symptoms have not yet been described.5,35 In the
present study, nursing home staff identified T1 in 61% of their patients,
through changes in fatigue and poor appetite. Symptoms such as pain,
dyspnea, or agitation did not predict imminent death. This is note-
worthy because physical symptoms of weakness do not explain the
initiation of pharmacological treatment. It is possible that the di-
agnoses of death (pneumonia, heart failure, and dementia) are trigger
factors for increased pain, dyspnea, and anxiety. Interestingly, the
prevalence of pain was not associated with agitation in our study,
although individual pain treatment has been demonstrated to be
correlated to the reduction of pain and agitation.13,36e38 Compared
with younger patients with cancer, the timely prognostication of
death is challenging due to the patient’s deterioration over a long time
period.35 Our findings should be used to enhance staff education in
care of dying nursing home patients because these symptoms are
challenging to distinguish: a prerequisite to provide proper symptom
management. Although Norwegian authorities are developing a sub-
specialization for nursing home physicians and a master’s degree for
geriatric nursing, these standards are not yet established. Regular
training and education of nursing home staff andmedical students are
priorities, but skills and competence regarding end-of-life care in
people with dementia vary considerably among institutions.
Limitations and Strengths
Our study used the continuous measures of ESAS symptom scores,
which to our knowledge are not validated in dying people with de-
mentia. ESAS has previously been used in the nursing home setting and
is the only end-of-life care instrument with relevant symptom list to
assess change in symptom intensity during treatment by a continuous
scale.13,39 However, the validity of proxy-rated intensity scores may
always be questionable in dying patients and people with dementia. A
further limitation is the lack of instruments to assess the quality of life
and quality of death and dying, which is an important consideration for
future studies. Additionally, to improve the situation for the dying old,
we would also recommend exploring convenient nonpharmacological
interventions, such as fresh air in the case of dyspnea. Beneficially, our
sample size at baseline was larger than comparable studies.10e14
However, when we assessed the association between newly initiated
pharmacological treatment and changes in pain and symptom intensity
we ended up with a rather low sample of 75 people.
Conclusion
In the present study, pain and symptom management were asso-
ciated with symptom relief in dying nursing home patients.
Nevertheless, too many people still experienced unacceptably high
levels of pain and distressing symptoms in the last days of life, which
emphasizes the critical need for user-specific guidelines, better
implementation, and staff education in nursing homes.
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Table 8: Demographic details, physical function, overall pain intensity and prevalence in study  
samples included in Papers 1 and 3 
 Paper 1 Paper 2 Paper 3 
Characteristics Pain-
BPSD  






Age, mean (SD) 85 (7) 84 (7) 86 (8) 86 (8)   
Gender, female % 74 70 71 64   
Dementia, % 87 76 83 87   
ADL function, Barthel 
mean (SD)§ 
8 (6)      
ADL function PSMS 
mean (SD)# 
   15 (5)   
Karnofsky (100-0)†    54 (30) 16 (10)  
MOBID-2 Smerteskala       
Hands, mean (SD) 0.9 (2.9)   0.4 (1.4) 1.3 (2.6) 0.6 (1.5) 
Arms, mean (SD) 1.7 (2.4)   1.0 (2.0) 1.9 (2.5) 1.0 (1.8) 
Legs, mean (SD) 2.3 (2.8)   1.3 (2.2) 2.9 (3.1) 1.4 (2.5) 
Turn, mean (SD) 2.0 (2.7)   1.2 (2.1) 3.6 (3.2) 2.6 (3.2) 
Sit, mean (SD) 1.8 (2.6)   1.1 (1.9) 3.0 (3.2) 0.9 (2.3) 
Head, mouth neck, mean 
(SD) 
1.2 (2.1)   0.6 (1.5) 2.0 (3.0) 0.9 (2.0) 
Heart, lung, chest, mean 
(SD) 
0.8 (1.7)   0.4 (1.2) 1.1 (2.2) 0.9 (2.0) 
Abdomen, mean (SD) 0.9 (1.8)   0.7 (1.6) 1.1 (2.1) 1.0 (1.9) 
Pelvis, genital organs, 
mean (SD) 
1.7 (2.6)   1.3 (2.3) 2.3 (2.7) 1.5 (2.3) 
Skin, mean (SD) 1.6 (2.4)   0.7 (1.7) 2.0 (3.0) 1.0 (2.2) 
Total score, mean (SD) 3.7 (2.6)   2.1 (2.1) 4.0 (3.0) 2.7 (2.8) 
Proportion pain 0-2, % 38   63 35 55 
Proportion pain 3-6, % 46   33 53 41 
Proportion pain 7-10, % 16   4 12 4 
§ADL scale (0-20): higher score equals better function 
#ADL scale (6-30): higher score equals more dependence 
†Higher score equals better function 
 
 
 
 
 
 
 
 
